Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota

Evidence of SARS-CoV-2 bacteriophage potential in... | F1000Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/11-292" }, "headline": "Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota", "datePublished": "2022-03-09T15:53:49", "dateModified": "2025-04-23T16:15:19", "author": [ { "@type": "Person", "name": "Mauro Petrillo" }, { "@type": "Person", "name": "Maddalena Querci" }, { "@type": "Person", "name": "Carlo Brogna" }, { "@type": "Person", "name": "Jessica Ponti" }, { "@type": "Person", "name": "Simone Cristoni" }, { "@type": "Person", "name": "Peter V Markov" }, { "@type": "Person", "name": "Andrea Valsesia" }, { "@type": "Person", "name": "Gabriele Leoni" }, { "@type": "Person", "name": "Alessandro Benedetti" }, { "@type": "Person", "name": "Thierry Wiss" }, { "@type": "Person", "name": "Guy Van den Eede" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": " Background In previous studies we have shown that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replicates in vitro in bacterial growth medium, that the viral replication follows bacterial growth, and it is influenced by the administration of specific antibiotics. These observations are compatible with a ‘bacteriophage-like’ behaviour of SARS-CoV-2. Methods We have further elaborated on these unusual findings and here we present the results of three different supplementary experiments: (1) an electron-microscope analysis of samples of bacteria obtained from a faecal sample of a subject positive to SARS-CoV-2; (2) mass spectrometric analysis of these cultures to assess the eventual de novo synthesis of SARS-CoV-2 spike protein; (3) sequencing of SARS-CoV-2 collected from plaques obtained from two different gut microbial bacteria inoculated with supernatant from faecal microbiota of an individual positive to SARS-CoV-2. Results Immuno-labelling with Anti-SARS-CoV-2 nucleocapsid protein antibody confirmed presence of SARS-CoV-2 both outside and inside bacteria. De novo synthesis of SARS-CoV-2 spike protein was observed, as evidence that SARS-CoV-2 RNA is translated in the bacterial cultures. In addition, phage-like plaques were spotted on faecal bacteria cultures after inoculation with supernatant from faecal microbiota of an individual positive to SARS-CoV-2. Bioinformatic analyses on the reads obtained by sequencing RNA extracted from the plaques revealed nucleic acid polymorphisms, suggesting different replication environment in the two bacterial cultures. Conclusions Based on these results we conclude that, in addition to its well-documented interactions with eukaryotic cells, SARS-CoV-2 may act as a bacteriophage when interacting with at least two bacterial species known to be present in the human microbiota. If the hypothesis proposed, i.e., that under certain conditions SARS-CoV-2 may multiply at the expense of human gut bacteria, is further substantiated, it would drastically change the model of acting and infecting of SARS-CoV-2, and most likely that of other human pathogenic viruses. " } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/11-292/v2", "name": "Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota" } } ] } Home Browse Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Petrillo M, Querci M, Brogna C et al. Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota [version 2; peer review: 1 approved, 2 approved with reservations] . F1000Research 2025, 11 :292 ( https://doi.org/10.12688/f1000research.109236.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Research Article Revised Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota [version 2; peer review: 1 approved, 2 approved with reservations] Mauro Petrillo https://orcid.org/0000-0002-6782-4704 1 * , Maddalena Querci https://orcid.org/0000-0002-0788-1627 2 * , Carlo Brogna https://orcid.org/0000-0001-6252-0595 3 * , [...] Jessica Ponti 2 * , Simone Cristoni 4 * , Peter V Markov 2 , Andrea Valsesia 2 , Gabriele Leoni 2,5 , Alessandro Benedetti 6 , Thierry Wiss 6 , Guy Van den Eede 7 Mauro Petrillo https://orcid.org/0000-0002-6782-4704 1 * , Maddalena Querci https://orcid.org/0000-0002-0788-1627 2 * , [...] Carlo Brogna https://orcid.org/0000-0001-6252-0595 3 * , Jessica Ponti 2 * , Simone Cristoni 4 * , Peter V Markov 2 , Andrea Valsesia 2 , Gabriele Leoni 2,5 , Alessandro Benedetti 6 , Thierry Wiss 6 , Guy Van den Eede 7 * Equal contributors PUBLISHED 23 Apr 2025 Author details Author details 1 Seidor Italy srl, Milano, 21029, Italy 2 European Commission Joint Research Centre, Ispra, 21027, Italy 3 Craniomed group srl, Montemiletto, 83038, Italy 4 ISB Ion Source & Biotechnologies Srl, Bresso, 20091, Italy 5 International School for Advanced Studies (SISSA), Trieste, 34136, Italy 6 European Commission Joint Research Centre, Karlsruhe, 76344, Germany 7 European Commission Joint Research Centre, Geel, 2440, Belgium Mauro Petrillo Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing Maddalena Querci Roles: Conceptualization, Funding Acquisition, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing Carlo Brogna Roles: Conceptualization, Formal Analysis, Investigation, Methodology, Writing – Review & Editing Jessica Ponti Roles: Formal Analysis, Investigation, Methodology, Visualization, Writing – Original Draft Preparation Simone Cristoni Roles: Conceptualization, Data Curation, Formal Analysis, Methodology, Visualization, Writing – Review & Editing Peter V Markov Roles: Writing – Original Draft Preparation, Writing – Review & Editing Andrea Valsesia Roles: Formal Analysis, Investigation, Methodology, Visualization, Writing – Review & Editing Gabriele Leoni Roles: Data Curation, Formal Analysis, Investigation, Software, Validation, Visualization, Writing – Review & Editing Alessandro Benedetti Roles: Formal Analysis, Investigation, Methodology, Visualization, Writing – Review & Editing Thierry Wiss Roles: Formal Analysis, Investigation, Methodology, Visualization, Writing – Review & Editing Guy Van den Eede Roles: Conceptualization, Funding Acquisition, Project Administration, Supervision, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS This article is included in the Emerging Diseases and Outbreaks gateway. This article is included in the Coronavirus (COVID-19) collection. Abstract Background In previous studies we have shown that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replicates in vitro in bacterial growth medium, that the viral replication follows bacterial growth, and it is influenced by the administration of specific antibiotics. These observations are compatible with a ‘bacteriophage-like’ behaviour of SARS-CoV-2. Methods We have further elaborated on these unusual findings and here we present the results of three different supplementary experiments: (1) an electron-microscope analysis of samples of bacteria obtained from a faecal sample of a subject positive to SARS-CoV-2; (2) mass spectrometric analysis of these cultures to assess the eventual de novo synthesis of SARS-CoV-2 spike protein; (3) sequencing of SARS-CoV-2 collected from plaques obtained from two different gut microbial bacteria inoculated with supernatant from faecal microbiota of an individual positive to SARS-CoV-2. Results Immuno-labelling with Anti-SARS-CoV-2 nucleocapsid protein antibody confirmed presence of SARS-CoV-2 both outside and inside bacteria. De novo synthesis of SARS-CoV-2 spike protein was observed, as evidence that SARS-CoV-2 RNA is translated in the bacterial cultures. In addition, phage-like plaques were spotted on faecal bacteria cultures after inoculation with supernatant from faecal microbiota of an individual positive to SARS-CoV-2. Bioinformatic analyses on the reads obtained by sequencing RNA extracted from the plaques revealed nucleic acid polymorphisms, suggesting different replication environment in the two bacterial cultures. Conclusions Based on these results we conclude that, in addition to its well-documented interactions with eukaryotic cells, SARS-CoV-2 may act as a bacteriophage when interacting with at least two bacterial species known to be present in the human microbiota. If the hypothesis proposed, i.e., that under certain conditions SARS-CoV-2 may multiply at the expense of human gut bacteria, is further substantiated, it would drastically change the model of acting and infecting of SARS-CoV-2, and most likely that of other human pathogenic viruses. READ ALL READ LESS Keywords SARS-CoV-2, COVID-19, gut microbiota Corresponding Author(s) Mauro Petrillo ( [email protected] ) Maddalena Querci ( [email protected] ) Guy Van den Eede ( [email protected] ) Close Corresponding authors: Mauro Petrillo, Maddalena Querci, Guy Van den Eede Competing interests: No competing interests were disclosed. Grant information: Funding was provided by the European Commission Joint Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Copyright: © 2025 Petrillo M et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Petrillo M, Querci M, Brogna C et al. Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota [version 2; peer review: 1 approved, 2 approved with reservations] . F1000Research 2025, 11 :292 ( https://doi.org/10.12688/f1000research.109236.2 ) First published: 09 Mar 2022, 11 :292 ( https://doi.org/10.12688/f1000research.109236.1 ) Latest published: 23 Apr 2025, 11 :292 ( https://doi.org/10.12688/f1000research.109236.2 ) Revised Amendments from Version 1 This version contains text additions within the "Discussion" section and changed figure legends following the comments and the suggestions made the reviewers, in the referee report on version 1. This version contains text additions within the "Discussion" section and changed figure legends following the comments and the suggestions made the reviewers, in the referee report on version 1. See the authors' detailed response to the review by M. Anwar Hossain and Md. Shaminur Rahman See the authors' detailed response to the review by Didier Raoult READ REVIEWER RESPONSES Introduction In a recent study, we reported a series of observations suggesting unexpected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – bacteria interactions. When cultivated in vitro faecal microbiota from infected individuals, we observed sustained growth in SARS-CoV-2 virus copies in 30-day bacterial cultures and SARS-CoV-2-related peptides were detected. 1 Furthermore, increase of viral loads was influenced by the administration of specific antibiotics The observations reported in Ref. 1 are in line with additional ones reported more recently, like evidence that gut virome is affected by the SARS-CoV-2 infection and may play an important role in the disease progression of coronavirus disease 2019 (COVID-19), 2 the presence of SARS-CoV-2 nucleoprotein (N) in intestinal epithelial cells of approximately 35% of patients with COVID-19 even several weeks or months after initial diagnosis, 3 the high rate of positive polymerase chain reaction (PCR) findings in more than one type of clinical specimen collected up to 43 days after COVID-19 patients had presented the first symptom. 4 To investigate these observations in more detail, we designed and carried out three different experiments, which make use of electron microscopy (EM), mass spectrometry and next-generation sequencing (NGS). The sample A described in Ref. 1 was used as starting material i.e . , an in vitro faecal microbiota culture obtained from a stool sample of a SARS-CoV-2 positive individual. Here we present the results of these experiments, which give evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota. Methods Ethical considerations Faecal samples were collected and handled by CranioMed S.R.L. from anonymous donors who agreed to participate in this study by signing informed consent, as foreseen by Italian legislation. No personal information (i.e. age, sex, blood serotype, severity of the disease, time of the collection, fatality, etc.) were collected. The experiments took place in 2021 at the ISB Ion Source & Biotechnologies Srl and Craniomed group srl laboratories, except for Next Generation Sequencing (conducted in service at IGA Tech, Italy). Samples’ preparation for image acquisition and data analyses were performed at JRC in Ispra and in Karlsruhe. The study is compliant with the JRC Scientific Integrity and Research Ethics guidance. Bacterial source and growth For all three experiments we used, as initial material, the sample A described in Ref. 1 i.e., an in vitro faecal microbiota culture obtained from a stool sample of a SARS-CoV-2 positive individual. The bacterial liquid culture derived from sample A, was maintained under stable conditions (here called again sample A). A corresponding negative control was used i.e., an in vitro faecal microbiota culture obtained from a faecal sample of a SARS-CoV-2 negative individual (sample B in Ref. 1 and here again called sample B). Bacteria were grown as described in Ref. 1 (see Materials and Methods , sections “ Medium preparation ” and “ Bacterial culture conditions ”). Briefly, faecal samples (stools) from confirmed COVID-19 affected and healthy individuals were obtained following written informed consent. Stool samples were kept at 4 °C until processing. The NutriSelect TM Plus nutrient broth (n. 70122-500G, Sigma-Aldrich) was used as bacterial growing broth. The medium was prepared following the protocol recommended by the supplier. Tubes/flasks with growing broth and bacteria were placed in an orbital shaker at 10 g at 37 °C and the liquid culture was left to grow progressively under anaerobic condition. Peptide mapping of spike in presence of 15 N The sample A bacterial culture was split in two (here called A1 and A2). In total, 0.25 ng of ammonium- 15 N chloride (>98 % nitrogen-15 isotope 15 N, >99% (CP), Sigma Aldrich Catalog # 900523) was added to sample A2 as additional source of nitrogen. Measurements of the viral RNA load were performed by using Luminex technology, as described in Ref. 1 (see Materials and Methods , sections “ Determination of viral RNA load ”). Briefly, the detection was performed by using NxTAG ® CoV Extended Panel (Luminex Corporation), a CE-marked (see https://covid-19-diagnostics.jrc.ec.europa.eu/devices/detail/266 ) real-time reverse transcriptase PCR assay detecting three SARS-CoV-2 genes on the MAGPIX ® NxTAG-enabled System MAGPIX instrument (Luminex Corporation Part Number MAGPIX-XPON4.1-CEIVD), and the AccuPlexTM SARS-CoV-2 Reference Material Kit (SeraCare) as reference standard with sequences from the SARS-CoV-2 genome. Multiplex 96-well plates were in house produced and RNA tags were added before the analysis in agreement with manufacturer instructions (Sigma Aldrich, https://www.sigmaaldrich.com/GB/en/product/sigma/luminex ) for their use on the MAGPIX ® instrument, and by following the protocol described by Chen et al. 5 These plates were transferred to a MAGPIX heater at 37 °C, and signal acquisition was performed by using the xPONENT and SYNCT software (Luminex Molecular Diagnostics) using a commercially available reference standard with sequences from the SARS-CoV-2 genome (AccuPlex TM SARS-CoV-2 Reference Material Kit, SeraCare). At day +7 from 15 N addition, aliquots from A1 and A2 were analysed to detect SARS-CoV-2 spike protein by peptide mapping, performed by using Surface-Activated Chemical Ionization/Electrospray Ionization mass spectrometry (SACI/ESI-MS) technology. The approach uses an ORBITRAP MS (ThermoFisher, San Jose, USA) coupled to a surface activated chemical ionization (SACI) /ESI source, and operated in positive ion mode. SARS-CoV-2 Spike Protein S1/S2 (ThermoFisher, Catalog # RP-87680) was used as an analytical standard. The characterisation of viral peptides was conducted as described in Ref. 1 (see Materials and Methods , section “ Characterisation of viral peptides by Mass Spectrometry (MS) ”). The following MS parameters were used: direct infusion flow rate, provided by means of a syringe pump, was set to 5 μL/min, with additional solvent provided at a flow rate of 100 μL/min. by an in-line HPLC pump; the N 2 drying gas temperature was 350°C; the N 2 nebulizing gas flow rate was 12 L/min. Two microscans (average) were acquired. The ionization source parameters were: ESI ionization voltage = 3,000 V, applied via a home-built external power supply to the spray needle; APCI needle current = 3,000 nA; SACI surface potential = 47 V for the in-source ionization, with an inter-capillary voltage gradient between –100 and –1,500 V, being employed to produce the CIMS effect; ion-source pressure = 2 bar. Pressure was varied by providing N2 gas via a tube connected to the ion source, and it was monitored by using a manometer (Stanley, Torino, Italy). Samples preparation for electron microscopy image acquisition and analysis Aliquots of sample A and corresponding negative control were collected and fixed overnight at 4 °C in Karnovsky 2% fixative freshly prepared in the laboratory using paraformaldehyde (Sigma Aldrich Catalog # 16005) 2% (w/v) in Na-Cacodilate (Sigma Aldrich Catalog # 233854) 0.05 M pH 7.4 and glutaraldehyde (Sigma Aldrich Catalog # G5882) 2% (v/v). Once fixed, they were washed 3 times with 0.05M Na-Cacodilate solution at pH 7.3, dehydrated in a graded series of ethanol (Sigma Aldrich Catalog # 493546) solutions in MilliQ water (30%-50%-75%-95% (v/v)) for 15 min. each, and 100% for 30 min.; 3 μL of suspension were deposited on Formvar Carbon coated 200 mesh copper grids (Agar Scientific, USA) and dried overnight in a desiccator. Some grids were directly analysed by JEOL JEM-2100 High Resolution-transmission electron microscope (TEM, JEOL, Italy) coupled with energy dispersive X-ray spectroscopy (EDX Bruker, Italy) at 120 kV, in TEM mode at magnification from ×3,000 to ×80,000 for imaging, and at 120kV magnification of ×80,000 and ×300,000 in STEM-Hypermap mode acquisition for elemental analysis. Some grids were immuno-labelled by rabbit polyclonal to SARS-CoV-2 nucleocapsid protein antibody (Abcam Catalog # ab273167) and anti-rabbit polyclonal IgG (whole molecule)-Gold 10 nm secondary antibody produced in goat (Sigma Aldrich catalog # G7402) followed by 5 min. uranyl acetate (Fluka catalog # Fluka 7394) 5% (w/v) stain. Sample A and the corresponding negative control were also immuno-labelled and embedded in epoxy resin (Sigma Aldrich, Epoxy Embedding Medium kit catalog # 45359) to prepare ultrafine slices for analysis as follows: both were fixed with a solution of 4% (v/v) paraformaldehyde and 0.1% (v/v) glutaraldehyde in 0.2 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, ThermoFisher Scientific catalog # J61017.AK) buffer for 15 min. and washed HEPES buffer two times. Samples were incubated in 4% (v/v) paraformaldehyde for 30 min. and washed 3 times for 5 min. each with phosphate buffered saline without CaCl 2 and MgCl 2 solution (PBS, ThermoFisher Scientific, Gibco catalog # 70011-36). Samples were incubated with block-solution (50 mM NH 4 Cl, 0.1% v/v saponin, 1% v/v Bovine Serum Albumin (BSA) in PBS, Sigma Aldrich catalog # 09718; # 47036; # B6917, respectively) for 30 min., and then with rabbit polyclonal to SARS-CoV-2 nucleocapsid protein primary antibody (Abcam Catalog # ab273167) diluted in block solution 1:100 (overnight). Pellets were washed 6 times for 2 min. each with PBS. Diluted Nanogold ® -Fab’ (goat polyclonal) or anti-rabbit IgG (Nanoprobes, catalog #2004) Fab fragments 1:100 in block solution was added to pellets, which were then incubated for 2 hours. Pellets were washed 6 times for 2 min. each with PBS and 3 times for 5 min. each in distilled water. Pellets were incubated with gold-enhancement mixture Gold-enhance EM kit (Nanoprobes catalog # 2113) for 5 min. and then washed 5 times for 5 min. each with distilled water and 3 times for 5 min. each with PBS. Pellets were post-fixed with the mixture of 2% (v/v) OsO 4 (Sigma Aldrich catalog # 75632) and 0.1M PBS (pH 6.8) for 25–30 min. on ice and washed 3 times with water. Thiocarbohydrizide 1% (w/v) in water (Sigma Aldrich catalog # 223220) was added for 5 min., followed by washing (3 times with water). After, pellets were treated with a mixture of 2% (v/v) OsO 4 and 3% (w/v) potassium ferrocyanide (Sigma Aldrich catalog # P9387) (1:1) for 25 min., and washed 3 times with water. Uranyl acetate (0.5% w/v) diluted in water was added, and pellets were stored overnight at +4 °C, then washed with water 6 times. Dehydration was conducted in a graded series of ethanol solutions from 50%, 70%, 90% (v/v) ethanol every 10 min. to 100% ethanol for 30 min., changing the 100% ethanol solution every 10 min. Mixture of epoxy resin was added to samples for 4 hours at room temperature. Specimens were incubated at 60 °C in the oven for 24 hours to allow resin polymerization. Ultrathin sections (50-70 nm) were obtained using Leica EM UC7 ultramicrotome (Leica, Italy) and stained for 25 min. with uranyl acetate (Fluka catalog # Fluka 7394) 5% (w/v) and freshly prepared Reynold’s lead citrate solution for 20 min., washed and dried. They were then collected on Formvar Carbon coated 200 mesh copper grids (Agar Scientific, USA) and imaged by TEM, as described above. Sample A and corresponding negative control were analysed by scanning electron microscopy (SEM) (Nova600i Nanolab, ThermoFisher, Eindhoven) using an acceleration voltage of 2 and 5 kV and the in-lens detector. The particles present in each of the analysed sample (independently of their nature) are irreversibly immobilized on a chip by self- assembling, due to electrostatic forces. The particles are separated and distributed randomly on the chip surface, facilitating the SEM characterization. The chip consists of a 0.025 mm 2 silicon chip coated with a 70 nm layer of polytetrafluoethylene (PTFE) and subsequently with a monolayer of poly (diallyldimethylammonium chloride) (PDDA) which confers a positive charge to the surface. Details on the preparation of the chip can be found in Ref. 6 . The chip is immersed overnight, and it can immobilize all the negatively charged particles present in the liquid sample. Then it is removed, thoroughly rinsed in ultrapure water, and dried under a gentle N 2 flow. A very thin (<10 nm) layer of carbon is deposited on the chip prior the SEM analysis. Plaque assay Faecalibacterium prausnitzii and Dorea formicigenerans strains were purchased at the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures (DSM Numbers 17677 and 3992, respectively). They were grown in liquid broth according to the information provided by the Leibniz Institute DSMZ (available at https://www.dsmz.de/collection/catalogue/details/culture/DSM-17677 and https://www.dsmz.de/collection/catalogue/details/culture/DSM-3992 , respectively), and after 7 days transferred on agar plates and grown at the same conditions (37 °C, humidity 95%, CO 2 5%). According to the information provided by the Leibniz Institute DSMZ, they have been both isolated from human faeces. After 3 days, plates were fully covered by bacteria. Each plate was schematically split in four areas and inoculated with: 0.40 μL double distilled water; 0.40 μL of a control supernatant negative to SARS-CoV-2; two aliquots (0.40 μL each) from two different supernatants positive to SARS-CoV-2. Aliquots of newly formed plaques were collected to perform NGS. Next Generation Sequencing Collected samples were centrifuged for 3 minutes at 3,000 rcf at room temperature. Nucleic acids were extracted from the supernatant by using the PureLink™ Viral RNA/DNA Mini Kit (ThermoFisher, Waltham, MA, United States) according to the manufacturer’s instructions. An amount of 10 μL of obtained total RNA was retrotranscribed using random hexamers, RNaseOUT™ Recombinant Ribonuclease Inhibitor and SuperScript™ II Reverse Transcriptase (all Life Technologies - Invitrogen), according to the manufacturers’ instructions. The SARS-CoV-2 genome was sequenced in service at IGA Tech (Italy) using a proprietary two-step PCR protocol for the amplification: 1) tiling in overlapping fragments of ~250 bp, 2) amplicon indexing. Libraries were sequenced on an Illumina NovSeq6000 platform, PE 150 bp mode. Raw data quality control FastQC (version 0.11.9, default parameters) (RRID:SCR_014583) 7 was used to obtain quality metrics from all sequencing raw data. Through FastQ Screen (version 0.14.1, default parameters) (RRID:SCR_000141) 7 and the MultiQC (version 1.11, default parameters) (RRID:SCR_014982) 8 tool run on the Galaxy server (RRID:SCR_006281), 9 outputs were inspected, and no sequencing issues were found from these quality checks. A summary of the quality checks and sequencing is provided in Figure S3. Mapping and variant calling Mapping of reads and variant calling were conducted on the Galaxy server by running the workflow “SARS-CoV-2 Illumina Amplicon pipeline - iVar based”. 10 Obtained consensus sequences were compared to reference by running COVID-Align. 11 Amino acid changes variations were identified at protein level by running Nextclade. 12 The comparison with known variations was made with respect to GISAID data (RRID:SCR_018279), 13 analysed by CoV-GLUE-Viz (update 15/09/2021). 14 Results To investigate more in detail our previous observations reported in Ref. 1 indicating SARS-CoV-2 – bacteria interaction, we designed and carried out three different experiments: 1. In vitro faecal microbiota from a SARS-CoV-2 positive individual (here called sample A) was grown in liquid culture and collected aliquots were analysed by EM image analysis to visualize the eventual presence of SARS-CoV-2 and to get some insight in the eventual interaction with bacteria. 2. Natural nitrogen-14 ( 14 N) and nitrogen-15 ( 15 N) isotopes, usually employed in metabolomics, proteomics and genomics functional studies, 15 , 16 were used to monitor the virus proliferation. Sample A was grown in presence of 14 N, and then 15 N was added. Presence of 15 N included in the spike protein was tested by performing peptide mapping analysis. 3. Faecalibacterium prausnitzii, member of Oscillospiraceae family (class Clostridia , NCBI:txid 853) and Dorea formicigenerans , member of Lachnospiraceae family (class Clostridia , NCBI:txid 39486) had previously been reported as being strongly reduced in COVID-19 patients. 17 , 18 For this reason, these two bacterial species were used for plaque assays to test aliquots of supernatants from sample A. Observed plaques were collected and further processed to perform NGS. We conducted all three experiments using, as initial material, the sample A described in Ref. 1 i.e . , an in vitro faecal microbiota culture obtained from a stool sample of a SARS-CoV-2 positive individual. The bacterial liquid culture derived from sample A (here also called sample A), was maintained under stable conditions. A corresponding negative control was used i.e., an in vitro faecal microbiota culture obtained from a faecal sample of a SARS-CoV-2 negative individual, called sample B (see Ref. 1 for details). Electron microscopy image analyses reveals the presence of virus-like particles inside and outside bacteria Aliquots of sample A and sample B (as negative control) were collected and analysed by SEM and by transmission electron microscope (TEM) coupled with energy dispersive X-ray spectroscopy. SEM analysis showed in sample A the presence of virus-like particles on the bacteria surface ( Figure 1 , panels a, b, c). This observation was also confirmed by TEM analysis ( Figure 2 , panels a, b, c) in which round virus-like particles of 25–100 nm size are clearly visible. In the SEM images, on carbon-coated samples, we observed many particles with round morphology attached to the bacteria wall. These round structures were not visible on bacteria from the control samples ( Figure 1 , panel d), which instead showed regular smooth surface. In the TEM analysis, particles darker than the substrate, showing rough surface, regular and spherical morphology are clearly visible and distinguishable from the bacteria structure. The particles are clearly interacting with the bacterial wall forming a sort of a bridge ( Figure 2 , panel b) and attached in different places of the wall ( Figure 2 a, b, c). Figure 1. Sample A and sample B images obtained by scanning electron microscope (SEM). Panels a (magnification ×20,000), b (magnification ×80,000), and c (magnification ×80,000) (sample A) show virus-like particles on bacteria surface from sample A (i.e., in vitro faecal microbiota culture obtained from a SARS-CoV-2 positive individual). Panel d (magnification ×80,000) shows the sample B (i.e., in vitro faecal microbiota culture obtained from a faecal sample of a SARS-CoV-2 negative individual) used as control. Figure 2. Sample A and sample B images obtained by transmission electron microscope (TEM). Panels a (magnification ×4,000), b (magnification ×20,000), and c (magnification ×30,000) (sample A, described in Figure 1 ) present whole bacteria fixed and dehydrated and show the presence of virus-like particles on bacteria surface strictly attached and interacting with the wall. Panels d (magnification ×3,000), e (magnification ×5,000), and f (magnification ×8,000) present whole bacteria not exposed to virus-like particles in sample B (described in Figure 1 ) used as control. In a subsequent step, employing immuno-labelling of the grid, the presence of SARS-CoV-2 nucleocapsid protein in sample A was confirmed ( Figure 3 , panel a). In addition, high amount of phosphorus (P) ( Figure 3 , panels b-c) is measured, as well as calcium and zinc (Ca and Zn, see supplementary Figure S1 in the Underlying data 38 ) in comparison to the background, which suggests that the observed structures are rich of P, which is negatively charged and thus it might absorb from the surrounding micro-environment positive charged ions, which is also in line with the observed lower levels of Ca and Zn in COVID-19 patients. 19 – 21 Figure 3. Sample A and sample B images obtained by transmission electron microscope coupled with energy dispersive X-ray spectroscopy (STEM-EDX). Panels a, b, and c (magnification ×80,000) (sample A, described in Figure 1 ) present whole bacteria fixed and dehydrated in the presence of virus-like particles on their surface strictly attached and interacting with the wall (panel a, acquisition in bright field). Each particle contains a high amount of phosphorus (red in panels b) as compared to the background; carbon is also present in (green in panel b) Panels d, e, and f (magnification ×60,000) show the same acquisition made on sample B (described in Figure 1 ) used as control (d=bright field; e=carbo; f=phosphorus). Immuno-labelled ultrafine slices of bacteria in sample A confirmed the presence of SARS-CoV-2 nucleocapsid protein both outside and inside bacteria ( Figure 4 , panels b-f ). Figure 4. Sample A and sample B images obtained by transmission electron microscope (TEM) with immuno-labelling of SARS-CoV-2 nucleocapsid protein. Presence of SARS-CoV-2 nucleocapsid protein conjugated with secondary Ab-gold 10 nm in whole bacterium (panel a, magnification ×20,000) and conjugated with secondary Ab NANOGOLD enhance in bacteria ultrafine slices (panels b, magnification ×6,000; c, magnification ×12,000; d, magnification ×20,000; e, magnification ×25,000; f, magnification ×80,000) from sample A (described in Figure 1 ). Ultrafine slices of negative control (Sample B, described in Figure 1 ) do not show significant presence of SARS-CoV-2 nucleocapsid protein (panels g, magnification ×3,000; h, magnification ×6,000; i, magnification ×8,000). The qualitative analysis of ultrafine slices showed the presence of SARS-CoV-2 nucleocapsid protein in bacteria with different grades of the ultrastructure damage, as compared to the negative control. Most of the protein was free in the cytoplasm and in some cases surrounded by a membrane ( Figure 4 , panel f ). The size and morphology of the enhanced gold signal particles were similar to what was observed in the whole bacteria samples. The same analyses performed on the negative controls ( Figure 1 , panel d, Figure 2 , panels d-e-f, Figure 3 , panels d-e-f, and Figure 4 , panels g-h-i) did not reveal any comparable signal. These images show the presence of virus-like particles inside and outside bacteria. Bacterial growth in presence of 15 N detected de novo synthesis of spike protein The experiment comprised of: (1) splitting of Sample A into two aliquots (here called A1 and A2), followed by addition of ammonium- 15 N chloride to sample A2 as a supplementary source of nitrogen (day 0); (2) growth of A1 and A2 for 7 days; (3) measurements of the viral RNA load by Luminex technology at day 0 and day 7. (4) peptide mapping analysis by mass spectrometry at day 7. Peptide mapping analysis revealed incorporation of 15 N in spike protein: after 7 days, spike labelled with 15 N ( Figure 5 ) and spike labelled with 14 N- 15 N were detected in sample A2, but not in sample A1. Sequences of 15 N-labelled spike peptides were determined ( Figure 6 , panel a) and mapped ( Figure 6 , panel b) on the SARS-CoV-2 reference spike protein (NCBI Reference Sequence: YP_009724390). Figure 5. Peptide mapping of SARS-CoV-2 spike protein. Peptide mapping of SARS-CoV-2 spike protein were acquired by means of liquid chromatography mass spectrometry associated to 14 N and 15 N profiles, and performed on an aliquot of sample A2. Figure 6. Characterization of spike peptides by Mass Spectrometry. Identified spike peptides labelled with 15 N and mapping on the reference spike protein (NCBI Reference Sequence: YP_009724390.1) are listed (panel a). They correspond to fragments obtained from trypsin digestion of the reference spike protein (panel b). Increase of viral RNA load was also observed in both A1 and A2, as already observed previously in Ref. 1 . These results indicate de novo synthesis of SARS-CoV-2 spike protein in human gut bacteria. Plaque assays to confirm sensitivity of commensal gut bacteria to SARS-CoV-2 F. prausnitzii and D. formicigenerans strains were individually grown in liquid broths. After 7 days, bacteria from each broth were transferred on agar plates and grown under the same conditions. When plates obtained full bacterial growth cover (i.e . , 3 days later), plates were each schematically split in four sectors, and inoculated with: • Aliquots of two different supernatants positive to SARS-CoV-2 – one per sector. • An aliquot of a control supernatant negative to SARS-CoV-2. • An aliquot of double distilled water. No plaque was observed in the areas where aliquots of double distilled water and of the control supernatant negative to SARS-CoV-2 where added ( Figure 7 , panels a), sectors dd H 2 O and negS and corresponding in panel b)). On the contrary, plaques were observed in the areas where aliquots from two different supernatants positive to SARS-CoV-2 were added ( Figure 7 , panels a) and b), sectors pos S1 and pos S2 ). Figure 7. Plaque assay. a) schematic split of the plates used in the assay in four sectors: dd H 2 O=double distilled water; negS = control supernatant negative to SARS-CoV-2; pos S1 and pos S2 = supernatants positive to SARS-CoV-2. b) observed plaques (red circled) were individually collected to perform NGS experiments. c) sample-specific nucleic acid changes identified in the two distinct sequence sets (column “BACT_source”): column “# Observations” represents the number of sequences in GISAID that, at the time of the analysis (15/9/2021) showed the same base change; column “base in the other one” indicates the base identified at the same position in the other sequence set; changes found in both sets are highlighted as rows with the same colour. Aliquots of plaques spotted on F. prausnitzii and D. formicigenerans growth were collected to perform NGS experiments. Obtained reads from F. prausnitzii and D. formicigenerans phage plaques map and cover 62% and 48% of the SARS-CoV-2 genomic reference sequence (NCBI Reference Sequence: NC_045512), respectively. Overviews on the quality of the sequencing experiments are provided in the Underlying data (as Figure S2), together with the obtained raw reads, two distinct SARS-CoV-2 consensus genomic sequences, and with the alignment of these sequences to the SARS-CoV-2 genomic reference sequence. 38 Many regions of SARS-CoV-2 were sequenced in both samples, and bioinformatics analyses (variant calling) revealed the presence of sample-specific nucleic acid changes i.e . , present in reads sequences from only one of the two grown bacterial species. Identified variations are reported in Table 1: only two of them are common. All nucleic acid changes except one (see Figure 7 , panel c) were already observed in other SARS-CoV-2 genomic sequences deposited in GISAID. These results give evidence of SARS-CoV-2 bacteriophage potential in the two bacterial species tested and normally present in human gut microbiota. Discussion We present a series of experiments to better understand previous observations that suggested a bacteriophage-like behaviour of SARS-CoV-2 in growing faecal microbiota derived from SARS-CoV-2 infected individuals. 1 Firstly, by electron microscopy image analyses, we observed virus like structure of around 25–100 nm size interacting with the outside of the wall of bacterial cells and found inside bacteria. The immuno-labelling with Anti-SARS-CoV-2 nucleocapsid protein antibody confirms the presence of SARS-CoV-2 both outside and inside bacteria. In addition, high levels of P, Ca and Zn were measured where spherical structures were observed. This is in line with previous findings that report spike and nucleocapsid proteins as highly phosphorylated 22 and patient affected by severe COVID-19 depleted in Zn 19 and Ca. 20 Secondly, drawing inspiration from the Meselson and Stahl experiment, who used two isotopes of nitrogen i.e., the common light 14 N, and the rare and heavier 15 N, as sources of nitrogen to demonstrate semi-conservative DNA replication, 23 we used the same in in vitro faecal microbiota cultures obtained from a stool sample of a SARS-CoV-2 positive individual to assess de novo synthesis of SARS-CoV-2 spike protein. 15 N-labelled spike protein was detected only in presence of 15 N as additional source of nitrogen and not in control sample (where only 14 N-labelled spike was identified). Such a synthesis went in parallel to an increase of the viral RNA load, in line with what already observed previously in. 1 These results provide evidence that SARS-CoV-2 RNA is both replicated and translated in the bacterial cultures of faecal origin. Finally, by performing plaque assays with aliquots of supernatants from cultures of faecal microbiota derived from SARS-CoV-2 infected individuals on pure cultures of two faecal anaerobic bacteria ( F. prausnitzii and D. formicigenerans ) reported to be strongly reduced in COVID-19 patients, we observed the formation of plaques characteristic for the presence of phages. RNA was extracted and NGS sequenced from aliquots individually collected from the plaques. The reads obtained from F. prausnitzii and D. formicigenerans viral plaques mapped a span of 62% and 48% of the SARS-CoV-2 genomic reference sequence respectively (NCBI Reference Sequence: NC_045512). Bioinformatic analyses revealed the presence of nucleic acid differences in comparison to the SARS-CoV-2 reference sequence. Interestingly, the two sets of bacterium-specific reads each displays a specific nucleic acid polymorphism signature, potentially suggesting different replication environment in the two bacterial cultures. The SARS-CoV-2 genome was not entirely sequenced, probably due to the chosen sequencing protocol, which (like any other protocol of sequencing SARS-CoV-2 genome) is not optimised for bacterial phage plaques from agar plates as starting material. Further sequencing experiments will be performed to demonstrate reproducibility. However, the two independent experiments we performed (each with a confirmed negative control), gave similar results. Each of them yielded NGS-derived SARS-CoV-2 genome sequences, with distinct nucleic acid variations, all of which have already been reported in other SARS-CoV-2 sequenced genomes, as reported in Figure 7 , panel c. The presence of identified variations not specific of any lineage, and the existence of culture-specific polymorphisms are in line with the intra-host quasispecies diversity of SARS-CoV-2, recently reported at both nucleic acid 24 and amino acid level. 25 In our experiments, these observations might be either a consequence of different lineages already present in the supernatant aliquots of infected bacteria used in the plaque assay, or a result of the two different bacterial “cellular machinery” environments, which the virus used when infecting two different species. Both consequences cannot be excluded. However, the presence of many identified variations not specific of any lineage, provides an indication that bacteria might be a potential source of novel SARS-CoV-2 mutations, and gives rise to the possibility that intra-host SARS-CoV-2 haplotypes might reflect different intestinal bacterial prior host environments of the virus. This observation would represent the basis for one of the proposed origins of the Omicron variant 26 i.e . , that Omicron (and other variants) might have evolved in the gut bacteria of one person. Linear regression models, like those used to dissect evolution, mode of transmission, and mutational landscape of SARS-CoV-2 variants 27 should consider the role of multiple bacterial hosts living in one infected holobiont. Likewise, investigations about the origin of the COVID-19 pandemic should add new key questions 28 in light of this. Since their discovery, interactions of phages with bacteria have been studied mainly in pairwise experiments. Only in recent years, growing numbers of studies have focused on the coevolution of phages and bacteria in communities, revealing the complexity of phage–bacterium interactions and evolution of phages in bacteria. 29 Wylezich et al. failed to identify tissue specific genetic adaptation of the virus in COVID-19 patients’ upper and lower respiratory tract. 30 One explanation might be that all cells of the same individual differ much less in terms of their replication or translation machinery, than taxonomically remote bacterial cells like those present in the human gut microbiota. In light of this, intra-bacterial diversity generation of the virus might potentially be more relevant than that occurring during human cells infection. Our results strongly suggest interactions of SARS-CoV-2 with bacteria in intestinal microbiota. The findings that SARS-CoV-2 is able to enter the cells of bacteria, which are part of the normal human gut microflora and is able to synthesize both the nucleic acid and viral peptides brings about a wide range of important potential implications for human health and particularly for the management and the control of the spread of this virus. For example, the ability of SARS-CoV-2 to infect and replicate in human gut bacteria could induce a situation where infected bacteria can harbour the virus for extended periods of time, potentially long after systemic infection in the human host has already been cleared. From an epidemiological point of view, this could contribute to much longer, potentially very long-term period of viral shedding through the faecal route, with a possible increased risk of onward transmission. Furthermore, prolonged persistence of a replicating virus in the intestinal lumen would render periodic renewals of systemic SARS-CoV-2 infection in the individual possible, thus potentially causing a relapse of COVID-19 without external reintroduction. All of these possibilities taken together would contribute to the augmentation of R 0 – the basic reproduction number of the virus, primarily through extending the duration of infectiousness component of R 0. 31 Gastrointestinal involvement is a frequent feature of long COVID-19 syndrome, 32 furthermore long-term presence of SARS-CoV-2 nucleocapsid protein was found in the gut mucosa of patients suffering from long COVID-19. 33 Our finding that intestinal bacteria may support SARS-CoV-2 replication therefore is likely to have important bearing on explaining the pathophysiology of the gastrointestinal symptoms during long COVID-19. On a separate note, the evidence we provide here that SARS-CoV-2 is capable of replicating in F.prausnitzii gives new significance to earlier evidence of inverse correlation between abundance of this anti-inflammatory bacterium in the intestines and COVID-19 severity, 17 suggesting indirectly that infection of symbiotic gut bacteria may correlate positively with disease severity. It is important to highlight that this study is limited to SARS-CoV-2 interaction with only two bacterial strains, i.e., F. prausnitzii and D. formicigenerans , chosen because both previously reported as strongly reduced in COVID-19 patients. 17 , 18 These are common gram-positive anaerobic commensals in the human gut, and thus it is likely they were also present in the faecal samples collected and used in this study. The interaction of SARS-CoV-2 with other common commensals, such as the facultative anaerobe gram-negative Escherichia coli should be investigated, too. At the population level, the ability of the virus to persist in gut bacteria may shed new light on the otherwise puzzling long-term stability of viral RNA in wastewater and public sewers, a phenomenon successfully used for local early warning SARS-CoV-2 surveillance. 34 Another aspect, related to the above is the possibility of replication of SARS-CoV-2 in bacteria outside of the human body – in the environment or in the gut or other microflora of other vertebrate hosts. From the point of view of epidemiological control, one of the fundamental obstacles to SARS-CoV-2 elimination is its ability to infect and be maintained as an epidemiological reservoir in multiple vertebrate species. 35 Thus, even if the elimination effort in humans was successful, frequent reintroductions of the infection from reservoir species could reverse the success. In this context, maintenance of the virus in bacteria in the environment could add one further potentially large and ubiquitous epidemiological reservoir for potential reintroduction of the infection back to humans or animal reservoirs. In the same vein, if SARS-CoV-2 can persist or replicate in bacteria in the human microbiota, such could also be the case in gut bacteria in other species with similar implications for longer infectivity and maintenance of the virus source. Given the predominantly gastrointestinal manifestations of an array of other, animals coronaviruses, 36 this is an even more pertinent question for SARS-CoV-2. We are fully aware that a ‘bacteriophage-like’ behaviour of SARS-CoV-2 has not been observed or described before, and that it is in contrast with the current knowledge of virology and molecular biology. It can’t be excluded that behind our observations and results there are new biological mechanisms not yet explored, such as those involving the interaction between anaerobic commensals of human gut and animal viruses through prokaryotic microvesicles, 37 evidently poorly studied. For this reason, we believe the findings presented in this work should be subject to controversy and verification by the scientific community. We invite other teams to verify whether they can reproduce results of this nature. Conclusions Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), and was responsible for the COVID-19 pandemic is so far considered to be able to infect only eukaryotic cells. Here we report experimental evidence that it can also infect bacteria, specifically two commensal gut bacterial species normally present in healthy human gut microflora. These results generate a wide range of important consequences for the epidemiology, ecology and public health aspect of the virus. We hope our results will contribute for a rethinking of SARS-CoV-2 biology and inform a more effective management and control in case of resurgence of COVID-19 pandemic. Data availability Underlying data Zenodo: Underlying data of “Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota https://doi.org/10.5281/zenodo.5905965 . 38 The project contains the following underlying data: • SupplementaryFigureS1.png (Virus-like particles on bacteria surface analysed by STEM-EDX technique.) • SupplementaryFigureS2.png (Overviews on the quality of the sequencing experiments). • SupplementaryFile01.fa (File with consensus sequences in fastA format). • SupplementaryFile02.txt (File with alignment of the obtained consensus sequences to SARS-CoV-2 reference sequence -,NCBI Reference Sequence: NC_045512.2). • RawFigures.tgz (compressed file with the raw unedited uncropped microscopy images). • ID2041-1-3992_S90_L001_R1_001.fastq.gz (compressed file with raw R1 reads from Dorea formicigenerans plaque). • ID2041-1-3992_S90_L001_R2_001.fastq.gz (compressed file with raw R2 reads from Dorea formicigenerans plaque). • ID2041-2-17677_S183_L001_R1_001.fastq.gz (compressed file with raw R1 reads from Faecalibacterium prausnitzii plaque). • ID2041-2-17677_S183_L001_R2_001.fastq.gz (compressed file with raw R2 reads from Faecalibacterium prausnitzii plaque). Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0). Accession numbers This project used the following NCBI taxonomy and reference sequences: • NCBI taxonomy: Faecalibacterium prausnitzii Accession number txid853 • NCBI taxonomy: Dorea formicigenerans Accession number txid39486 • NCBI Protein: surface glycoprotein [Severe acute respiratory syndrome coronavirus 2]. https://identifiers.org/ncbiprotein:YP_009724390 . • NCBI Protein: Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome. https://identifiers.org/ncbiprotein:NC_045512 Acknowledgements We gratefully acknowledge: • the Authors and the Originating laboratories where the clinical specimen or virus isolate was first obtained and the Submitting laboratories, where sequence data have been generated and submitted to GISAID. • Prof. Remo Sanges (SISSA, Scuola Internazionale Superiore di Studi Avanzati, Trieste, Italy) for the fruitful discussions we had together. • The Advanced Microscopy and Imaging Facility of TIGEM (Naples, Italy) for the provision of preparing samples and analysing them by Electron Microscopy. • The IGATech Genomics Research Service (Udine, Italy) for the provision of preparing samples and performing Next Generation Sequencing. References 1. Petrillo M, Brogna C, Cristoni S, et al. : Increase of SARS-CoV-2 RNA load in faecal samples prompts for rethinking of SARS-CoV-2 biology and COVID-19 epidemiology [version 3; peer review: 2 approved]. F1000Res. 2021; 10 (370). Publisher Full Text 2. Lu ZH, Zhou HW, Wu WK, et al. : Alterations in the Composition of Intestinal DNA Virome in Patients With COVID-19. Front. Cell. Infect. Microbiol. 2021; 11 : 790422. PubMed Abstract | Publisher Full Text 3. Gaebler C, Wang Z, Lorenzi JCC, et al. : Evolution of antibody immunity to SARS-CoV-2. Nature. 2021; 591 : 639–644. PubMed Abstract | Publisher Full Text 4. Anjos D, Fiaccadori FS, Servian C, et al. : SARS-CoV-2 loads in urine, sera and stool specimens in association with clinical features of COVID-19 patients. J. Clin. Virol. Plus. 2022; 2 : 100059. Publisher Full Text 5. Chen JH, Yip CC, Chan JF, et al. : Clinical Performance of the Luminex NxTAG CoV Extended Panel for SARS-CoV-2 Detection in Nasopharyngeal Specimens from COVID-19 Patients in Hong Kong. J. Clin. Microbiol. 2020; 58 : e00936–e00920. PubMed Abstract | Publisher Full Text 6. Desmet C, Valsesia A, Oddo A, et al. : Characterisation of nanomaterial hydrophobicity using engineered surfaces. J. Nanopart. Res. 2017; 19 : 117. PubMed Abstract | Publisher Full Text 7. Wingett SW, Andrews S: FastQ Screen: A tool for multi-genome mapping and quality control. F1000Res. 2018; 7 : 1338. PubMed Abstract | Publisher Full Text 8. Ewels P, Magnusson M, Lundin S, et al. : MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016; 32 : 3047–3048. PubMed Abstract | Publisher Full Text 9. Afgan E, Baker D, Batut B, et al. : The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res. 2018; 46 : W537–W544. PubMed Abstract | Publisher Full Text 10. Maier W, Bray S, van den Beek M , et al. : Freely accessible ready to use global infrastructure for SARS-CoV-2 monitoring. bioRxiv [Preprint]. 2021. Publisher Full Text 11. Lemoine F, Blassel L, Voznica J, et al. : COVID-Align: accurate online alignment of hCoV-19 genomes using a profile HMM. Bioinformatics. 2021; 37 : 1761–1762. PubMed Abstract | Publisher Full Text 12. Hadfield J, Megill C, Bell SM, et al. : Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018; 34 : 4121–4123. PubMed Abstract | Publisher Full Text Reference Source 13. Shu Y, McCauley J: GISAID: Global initiative on sharing all influenza data - from vision to reality. Euro. Surveill. 2017; 22 : 30494. PubMed Abstract | Publisher Full Text 14. Singer J, Gifford R, Cotten M, Robertson D: CoV-GLUE: A Web Application for Tracking SARS-CoV-2 Genomic Variation.2020. Publisher Full Text Reference Source Reference Source 15. Webhofer C, Zhang Y, Brusis J, et al. : 15 N metabolic labeling: evidence for a stable isotope effect on plasma protein levels and peptide chromatographic retention times. J. Proteome. 2013; 88 : 27–33. PubMed Abstract | Publisher Full Text 16. Filiou MD, Soukupova M, Rewerts C, et al. : Variability assessment of (15) N metabolic labeling-based proteomics workflow in mouse plasma and brain. Mol. BioSyst. 2015; 11 : 1536–1542. PubMed Abstract | Publisher Full Text 17. Zuo T, Zhang F, Lui GCY, et al. : Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020; 159 : 944–955.e8. PubMed Abstract | Publisher Full Text 18. Yeoh YK, Zuo T, Lui GC, et al. : Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021; 70 : 698–706. PubMed Abstract | Publisher Full Text 19. Jothimani D, Kailasam E, Danielraj S, et al. : COVID-19: Poor outcomes in patients with zinc deficiency. Int. J. Infect. Dis. 2020; 100 : 343–349. PubMed Abstract | Publisher Full Text 20. Bennouar S, Cherif AB, Kessira A, et al. : Vitamin D Deficiency and Low Serum Calcium as Predictors of Poor Prognosis in Patients with Severe COVID-19. J. Am. Coll. Nutr. 2021; 40 : 104–110. PubMed Abstract | Publisher Full Text 21. Elham AS, Azam K, Azam J, et al. : Serum vitamin D, calcium, and zinc levels in patients with COVID-19. Clin Nutr ESPEN. 2021; 43 : 276–282. PubMed Abstract | Publisher Full Text 22. Bouhaddou M, Memon D, Meyer B, et al. : The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell. 2020; 182 : 685–712.e19. PubMed Abstract | Publisher Full Text 23. Meselson M, Stahl FW: THE REPLICATION OF DNA IN ESCHERICHIA COLI. Proc. Natl. Acad. Sci. U. S. A. 1958; 44 : 671–682. PubMed Abstract | Publisher Full Text | Free Full Text 24. Armero A, Berthet N, Avarre JC: Intra-Host Diversity of SARS-Cov-2 Should Not Be Neglected: Case of the State of Victoria, Australia. Viruses. 2021; 13 : 133. PubMed Abstract | Publisher Full Text 25. Gallais F, Pible O, Gaillard JC, et al. : Heterogeneity of SARS-CoV-2 virus produced in cell culture revealed by shotgun proteomics and supported by genome sequencing. Anal. Bioanal. Chem. 2021; 413 : 7265–7275. PubMed Abstract | Publisher Full Text 26. Mallapaty S: Where did Omicron come from? Three key theories. Nature. 2022; 602 : 26–28. PubMed Abstract | Publisher Full Text 27. Chakraborty C, Sharma AR, Bhattacharya M, et al. : Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants. MBio. 2021; 12 : e0114021. PubMed Abstract | Publisher Full Text 28. Worobey M: Dissecting the early COVID-19 cases in Wuhan. Science. 2021; 374 : 1202–1204. PubMed Abstract | Publisher Full Text 29. Chevallereau A, Pons BJ, van Houte S , et al. : Interactions between bacterial and phage communities in natural environments. Nat. Rev. Microbiol. 2021; 20 : 49–62. PubMed Abstract | Publisher Full Text 30. Wylezich C, Schaller T, Claus R, et al. : Whole-genome analysis of SARS-CoV-2 samples indicate no tissue specific genetic adaptation of the virus in COVID-19 patients’ upper and lower respiratory tract. Diagn. Microbiol. Infect. Dis. 2021; 101 : 115520. PubMed Abstract | Publisher Full Text 31. Heesterbeek JAP, Dietz K: The concept of R 0 in epidemic theory. Stat. Neerland. 1996; 50 : 89–110. Publisher Full Text 32. Liang L, Yang B, Jiang N, et al. : Three-month Follow-up Study of Survivors of Coronavirus Disease 2019 after Discharge. J. Korean Med. Sci. 2020; 35 : e418. PubMed Abstract | Publisher Full Text 33. Arostegui D, Castro K, Schwarz S, et al. : Persistent SARS-CoV-2 Nucleocapsid Protein Presence in the Intestinal Epithelium of a Pediatric Patient 3 Months After Acute Infection. JPGN Reports. 2022; 3 : e152. Publisher Full Text 34. McClary-Gutierrez JS, Mattioli MC, Marcenac P, et al. : SARS-CoV-2 Wastewater Surveillance for Public Health Action. Emerg. Infect. Dis. 2021; 27 : 1–8. PubMed Abstract | Publisher Full Text 35. Murphy HL, Ly H: Understanding the prevalence of SARS-CoV-2 (COVID-19) exposure in companion, captive, wild, and farmed animals. Virulence. 2021; 12 : 2777–2786. PubMed Abstract | Publisher Full Text 36. Le Poder S: Feline and Canine Coronaviruses: Common Genetic and Pathobiological Features. Adv. Virol. 2011; 2011 : 609411–609465. PubMed Abstract | Publisher Full Text 37. Mobarak H, Javid F, Narmi MT, et al. : Prokaryotic microvesicles Ortholog of eukaryotic extracellular vesicles in biomedical fields. Cell Commun. Signal. 2024 Jan 30; 22 (1): 80. PubMed Abstract | Publisher Full Text | Free Full Text 38. Petrillo M, Querci M, Brogna M, et al. : Underlying data of “Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota” (Version v2). Zenodo. 2022. Publisher Full Text Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 09 Mar 2022 ADD YOUR COMMENT Comment Author details Author details 1 Seidor Italy srl, Milano, 21029, Italy 2 European Commission Joint Research Centre, Ispra, 21027, Italy 3 Craniomed group srl, Montemiletto, 83038, Italy 4 ISB Ion Source & Biotechnologies Srl, Bresso, 20091, Italy 5 International School for Advanced Studies (SISSA), Trieste, 34136, Italy 6 European Commission Joint Research Centre, Karlsruhe, 76344, Germany 7 European Commission Joint Research Centre, Geel, 2440, Belgium Mauro Petrillo Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing Maddalena Querci Roles: Conceptualization, Funding Acquisition, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing Carlo Brogna Roles: Conceptualization, Formal Analysis, Investigation, Methodology, Writing – Review & Editing Jessica Ponti Roles: Formal Analysis, Investigation, Methodology, Visualization, Writing – Original Draft Preparation Simone Cristoni Roles: Conceptualization, Data Curation, Formal Analysis, Methodology, Visualization, Writing – Review & Editing Peter V Markov Roles: Writing – Original Draft Preparation, Writing – Review & Editing Andrea Valsesia Roles: Formal Analysis, Investigation, Methodology, Visualization, Writing – Review & Editing Gabriele Leoni Roles: Data Curation, Formal Analysis, Investigation, Software, Validation, Visualization, Writing – Review & Editing Alessandro Benedetti Roles: Formal Analysis, Investigation, Methodology, Visualization, Writing – Review & Editing Thierry Wiss Roles: Formal Analysis, Investigation, Methodology, Visualization, Writing – Review & Editing Guy Van den Eede Roles: Conceptualization, Funding Acquisition, Project Administration, Supervision, Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information Funding was provided by the European Commission Joint Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Article Versions (2) version 2 Revised Published: 23 Apr 2025, 11:292 https://doi.org/10.12688/f1000research.109236.2 version 1 Published: 09 Mar 2022, 11:292 https://doi.org/10.12688/f1000research.109236.1 Copyright © 2025 Petrillo M et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Petrillo M, Querci M, Brogna C et al. Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota [version 2; peer review: 1 approved, 2 approved with reservations] . F1000Research 2025, 11 :292 ( https://doi.org/10.12688/f1000research.109236.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 2 VERSION 2 PUBLISHED 23 Apr 2025 Revised Views 0 Cite How to cite this report: Sun Z. Reviewer Report For: Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota [version 2; peer review: 1 approved, 2 approved with reservations] . F1000Research 2025, 11 :292 ( https://doi.org/10.5256/f1000research.180605.r380905 ) The direct URL for this report is: https://f1000research.com/articles/11-292/v2#referee-response-380905 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 28 May 2025 Zhonghan Sun , Fudan University, Shanghai, Shanghai, China Approved with Reservations VIEWS 0 https://doi.org/10.5256/f1000research.180605.r380905 In this article, Mauro et.al reported that SARS-CoV-2 may behave in a bacteriophage-like manner by infecting and replicating within certain human gut commensal bacteria. The authors present electron microscopy imaging, stable isotope labeling mass spectrometry, and plaque assays to support this hypothesis. While ... Continue reading READ ALL In this article, Mauro et.al reported that SARS-CoV-2 may behave in a bacteriophage-like manner by infecting and replicating within certain human gut commensal bacteria. The authors present electron microscopy imaging, stable isotope labeling mass spectrometry, and plaque assays to support this hypothesis. While the research question is bold and potentially impactful if substantiated, several aspects of the methodology, data interpretation, and controls need to be more rigorously addressed before strong conclusions can be drawn. Major Comments: 1. The claim that SARS-CoV-2 replicates in gut bacteria is bold and unconventional. While the authors observed some viral protein signals and genome fragments in bacterial cultures, the current data cannot fully exclude alternative explanations such as uptake of viral RNA, protein adsorption, or contamination. 2. The evidence for de novo synthesis of spike protein in bacterial cultures is primarily based on ^15N-labeled peptides detected by MS. However, key supporting data such as MS/MS spectra, peptide confidence scores, and comparison with spike standard spectra are not shown. 3. The presence of virus-like particles on bacterial surfaces and within cells is interesting. Yet, without quantitative analysis or consistent morphology, the conclusions drawn from EM remain speculative. 4. The study would benefit from additional negative controls to better exclude passive adsorption or contamination. 5. The conclusion that SARS-CoV-2 replicates in gut bacteria and exhibits bacteriophage-like behavior is not fully supported by the current evidence. A more cautious interpretation is warranted. Is the work clearly and accurately presented and does it cite the current literature? Partly Is the study design appropriate and is the work technically sound? Partly Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Not applicable Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Partly Competing Interests: No competing interests were disclosed. Reviewer Expertise: Microbiology, cardiometabolic disease I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Sun Z. Reviewer Report For: Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota [version 2; peer review: 1 approved, 2 approved with reservations] . F1000Research 2025, 11 :292 ( https://doi.org/10.5256/f1000research.180605.r380905 ) The direct URL for this report is: https://f1000research.com/articles/11-292/v2#referee-response-380905 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Version 1 VERSION 1 PUBLISHED 09 Mar 2022 Views 0 Cite How to cite this report: Raoult D. Reviewer Report For: Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota [version 2; peer review: 1 approved, 2 approved with reservations] . F1000Research 2025, 11 :292 ( https://doi.org/10.5256/f1000research.120713.r371575 ) The direct URL for this report is: https://f1000research.com/articles/11-292/v1#referee-response-371575 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 28 Mar 2025 Didier Raoult , Institut Hospitalo-Universitaire Méditerranée-Infection, Faculté de médecine, Aix-Marseille Université, URMITE, Marseille, France Approved VIEWS 0 https://doi.org/10.5256/f1000research.120713.r371575 This work is very interesting, but it overturns a well-established theory about the host specificity of viruses. The idea that a mammalian eukaryotic cell virus could multiply in bacteria in a way comparable to bacteriophages is a staggering one. The ... Continue reading READ ALL This work is very interesting, but it overturns a well-established theory about the host specificity of viruses. The idea that a mammalian eukaryotic cell virus could multiply in bacteria in a way comparable to bacteriophages is a staggering one. The techniques employed by the authors are comprehensive, ranging from electron microscopy to nucleotide sequence, proteomic evaluation and in situ hybridization. Technically, this work is indisputable. The only thing that could call into question the quality and significance of this work would be the existence of a fraud that I am unable to detect. In practical terms, I think it's very important to accept this work and subject it to controversy and verification by other scientific teams. With this in mind, our team will be moving quickly to verify whether we can reproduce results of this nature. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Not applicable Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Microbiology I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Raoult D. Reviewer Report For: Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota [version 2; peer review: 1 approved, 2 approved with reservations] . F1000Research 2025, 11 :292 ( https://doi.org/10.5256/f1000research.120713.r371575 ) The direct URL for this report is: https://f1000research.com/articles/11-292/v1#referee-response-371575 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 26 Apr 2025 Mauro Petrillo , Seidor Italy srl, Milano, 21029, Italy 26 Apr 2025 Author Response Dear Dr. Raoult, ​​​​​​We thank you for your open-mindedness and for encouraging a broader dialogue around this work. We are committed to scientific transparency, and we are pleased to read that ... Continue reading Dear Dr. Raoult, ​​​​​​We thank you for your open-mindedness and for encouraging a broader dialogue around this work. We are committed to scientific transparency, and we are pleased to read that the reviewer’s team intends to attempt replication of our results. We believe that only through open scientific discourse and independent validation can the implications of such findings be fully understood and either confirmed or refuted. For this reason, the following sentence has been added at the end of the paper: “ We are fully aware that a ‘bacteriophage-like’ behaviour of SARS-CoV-2 has not been observed nor described before, and that it is in contrast with the current knowledge of virology and molecular biology. It can’t be excluded that behind our observations and results there are new biological mechanisms not yet explored, such as those involving the interaction between anaerobic commensals of human gut and animal viruses through prokaryotic microvesicles [https://doi.org/10.1186/s12964-023-01414-8], evidently poorly studied. For this reason, we believe the findings presented in this work should be subject to controversy and verification by the scientific community. We invite other teams to verify whether they can reproduce results of this nature. ” Thank you again for your thoughtful evaluation and the opportunity to improve our work. Sincerely, Mauro Petrillo, On behalf of all authors Dear Dr. Raoult, ​​​​​​We thank you for your open-mindedness and for encouraging a broader dialogue around this work. We are committed to scientific transparency, and we are pleased to read that the reviewer’s team intends to attempt replication of our results. We believe that only through open scientific discourse and independent validation can the implications of such findings be fully understood and either confirmed or refuted. For this reason, the following sentence has been added at the end of the paper: “ We are fully aware that a ‘bacteriophage-like’ behaviour of SARS-CoV-2 has not been observed nor described before, and that it is in contrast with the current knowledge of virology and molecular biology. It can’t be excluded that behind our observations and results there are new biological mechanisms not yet explored, such as those involving the interaction between anaerobic commensals of human gut and animal viruses through prokaryotic microvesicles [https://doi.org/10.1186/s12964-023-01414-8], evidently poorly studied. For this reason, we believe the findings presented in this work should be subject to controversy and verification by the scientific community. We invite other teams to verify whether they can reproduce results of this nature. ” Thank you again for your thoughtful evaluation and the opportunity to improve our work. Sincerely, Mauro Petrillo, On behalf of all authors Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 26 Apr 2025 Mauro Petrillo , Seidor Italy srl, Milano, 21029, Italy 26 Apr 2025 Author Response Dear Dr. Raoult, ​​​​​​We thank you for your open-mindedness and for encouraging a broader dialogue around this work. We are committed to scientific transparency, and we are pleased to read that ... Continue reading Dear Dr. Raoult, ​​​​​​We thank you for your open-mindedness and for encouraging a broader dialogue around this work. We are committed to scientific transparency, and we are pleased to read that the reviewer’s team intends to attempt replication of our results. We believe that only through open scientific discourse and independent validation can the implications of such findings be fully understood and either confirmed or refuted. For this reason, the following sentence has been added at the end of the paper: “ We are fully aware that a ‘bacteriophage-like’ behaviour of SARS-CoV-2 has not been observed nor described before, and that it is in contrast with the current knowledge of virology and molecular biology. It can’t be excluded that behind our observations and results there are new biological mechanisms not yet explored, such as those involving the interaction between anaerobic commensals of human gut and animal viruses through prokaryotic microvesicles [https://doi.org/10.1186/s12964-023-01414-8], evidently poorly studied. For this reason, we believe the findings presented in this work should be subject to controversy and verification by the scientific community. We invite other teams to verify whether they can reproduce results of this nature. ” Thank you again for your thoughtful evaluation and the opportunity to improve our work. Sincerely, Mauro Petrillo, On behalf of all authors Dear Dr. Raoult, ​​​​​​We thank you for your open-mindedness and for encouraging a broader dialogue around this work. We are committed to scientific transparency, and we are pleased to read that the reviewer’s team intends to attempt replication of our results. We believe that only through open scientific discourse and independent validation can the implications of such findings be fully understood and either confirmed or refuted. For this reason, the following sentence has been added at the end of the paper: “ We are fully aware that a ‘bacteriophage-like’ behaviour of SARS-CoV-2 has not been observed nor described before, and that it is in contrast with the current knowledge of virology and molecular biology. It can’t be excluded that behind our observations and results there are new biological mechanisms not yet explored, such as those involving the interaction between anaerobic commensals of human gut and animal viruses through prokaryotic microvesicles [https://doi.org/10.1186/s12964-023-01414-8], evidently poorly studied. For this reason, we believe the findings presented in this work should be subject to controversy and verification by the scientific community. We invite other teams to verify whether they can reproduce results of this nature. ” Thank you again for your thoughtful evaluation and the opportunity to improve our work. Sincerely, Mauro Petrillo, On behalf of all authors Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Hossain MA and Rahman MS. Reviewer Report For: Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota [version 2; peer review: 1 approved, 2 approved with reservations] . F1000Research 2025, 11 :292 ( https://doi.org/10.5256/f1000research.120713.r154688 ) The direct URL for this report is: https://f1000research.com/articles/11-292/v1#referee-response-154688 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 25 Nov 2022 M. Anwar Hossain , Department of Microbiology, University of Dhaka, Dhaka, Bangladesh Md. Shaminur Rahman , Department of Microbiology, Jashore University of Science and Technology, Sadhinata Sarak, Bangladesh Approved with Reservations VIEWS 0 https://doi.org/10.5256/f1000research.120713.r154688 This work is nicely designed but only two bacterial strains ( Faecalibacterium prausnitzii and Dorea formicigenerans strain) were tested here. The Major comments are listed below: On which basis these two bacteria were taken? ... Continue reading READ ALL This work is nicely designed but only two bacterial strains ( Faecalibacterium prausnitzii and Dorea formicigenerans strain) were tested here. The Major comments are listed below: On which basis these two bacteria were taken? " Faecalibacterium prausnitzii and Dorea formicigenerans strains were purchased at the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures"; Did they confirm that these bacteria were also present in the human gut from where they collected samples? Through NGS, they sequenced the SARS-CoV-2 genome. " host specific” nucleic acid changes" Did the author sequence these genomes before inoculation to the bacterial culture? This variation might be the different variants of SARS-CoV-2 variants as these were collected from two different suspected patients. What evidence the author is going to give here as the genome changing inside the multiplication of bacterial strains? Bacteriophage potential is showing only the two isolates? What will happen if E. coli is used here? Add discussion on which mechanisms the virus multiplies inside prokaryotic cells as we know it is an animal virus. Clear figure legends from Figure 1 to figure 4. The author can include here the name of the isolates. Submit those genome and raw sequence file to NCBI or other repository. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Partly Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Not applicable Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Virology, Genomics, Metagenomics, Vaccine Development We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Hossain MA and Rahman MS. Reviewer Report For: Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota [version 2; peer review: 1 approved, 2 approved with reservations] . F1000Research 2025, 11 :292 ( https://doi.org/10.5256/f1000research.120713.r154688 ) The direct URL for this report is: https://f1000research.com/articles/11-292/v1#referee-response-154688 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 29 Nov 2022 Mauro Petrillo , Seidor Italy srl, Milano, 21029, Italy 29 Nov 2022 Author Response Dear M. Anwar Hossain and Md. Shaminur Rahma, Thanks a lot for your valuable comments and suggestions that you have provided in the report. We will address all ... Continue reading Dear M. Anwar Hossain and Md. Shaminur Rahma, Thanks a lot for your valuable comments and suggestions that you have provided in the report. We will address all of them, and wait for those of other reviewers, in order to provide a fully revised version of the manuscript. Best regards, Mauro Petrillo, on behalf of the authors. Dear M. Anwar Hossain and Md. Shaminur Rahma, Thanks a lot for your valuable comments and suggestions that you have provided in the report. We will address all of them, and wait for those of other reviewers, in order to provide a fully revised version of the manuscript. Best regards, Mauro Petrillo, on behalf of the authors. Competing Interests: No competing interests were disclosed. Close Report a concern Author Response 14 Apr 2025 Mauro Petrillo , Seidor Italy srl, Milano, 21029, Italy 14 Apr 2025 Author Response Dear Dr. Anwar Hossain and Dr. Md. Shaminur Rahman, We sincerely thank you for the constructive feedback on our manuscript. We appreciate the opportunity to clarify and revise our work. ... Continue reading Dear Dr. Anwar Hossain and Dr. Md. Shaminur Rahman, We sincerely thank you for the constructive feedback on our manuscript. We appreciate the opportunity to clarify and revise our work. Below, we provide detailed responses to each of the comments raised. Comment 1: “On which basis these two bacteria were taken?” Response: As we indicated in the text, the selection of Faecalibacterium prausnitzii and Dorea formicigenerans was justified by the fact that both had previously been reported as being strongly reduced in COVID-19 patients (Ref. 17 and Ref. 18). We rephrased the Results section to better clarify this point. Comment 2: “Did they confirm that these bacteria were also present in the human gut from where they collected samples?” Response: Thank you for this comment. We did not check whether these two species were present in our collected samples. However, these bacteria are common gram-positive anaerobic commensals in the human gut, and thus it is likely they were also present in the faecal samples collected and used in this study. We have clarified this in the Discussion section by revising the text as follows: “It is important to highlight that this study is limited to SARS-CoV-2 interaction with only two bacterial strains, i.e., F. prausnitzii and D. formicigenerans, chosen because both were previously reported as strongly reduced in COVID-19 patients 17,18 . These are common gram-positive anaerobic commensals in the human gut, and thus it is likely they were also present in the faecal samples collected and used in this study.” Comment 3: “Through NGS, they sequenced the SARS-CoV-2 genome. "host specific” nucleic acid changes" Did the author sequence these genomes before inoculation to the bacterial culture? This variation might be the different variants of SARS-CoV-2 variants as these were collected from two different suspected patients. What evidence the author is going to give here as the genome changing inside the multiplication of bacterial strains?” Response: Thank you for the correct observation. We revised the text and replaced the term “host specific” with “sample-specific”. In addition, we revised the Discussion section in which this point is discussed by adding a sentence, here underlined as follows: “In our experiments, these observations might be either a consequence of different lineages already present in the supernatant aliquots of infected bacteria used in the plaque assay, or a result of the two different bacterial “cellular machinery” environments, which the virus used when infecting two different species. Both consequences cannot be excluded. However, the presence of many identified variations not specific of any lineage provides an indication that bacteria might be a potential source of novel SARS-CoV-2 mutations, and gives rise to the possibility that intra-host SARS-CoV-2 haplotypes might reflect different intestinal bacterial prior host environments of the virus.” Comment 4: “Bacteriophage potential is showing only the two isolates? What will happen if E. coli is used here?” Response: We appreciate this suggestion. Our study was a preliminary investigation focusing on human gut-resident commensals and E. coli was not included in the study. However, we acknowledge the value of using E. coli as a model organism in future studies to generalise the findings and explore potential broader bacteriophage-like interactions. This has been discussed in the revised Discussion section, by adding the following sentence: “It is important to highlight that this study is limited to SARS-CoV-2 interaction with only two bacterial strains, i.e., F. prausnitzii and D. formicigenerans, chosen because both were previously reported as strongly reduced in COVID-19 patients 17,18 . These are common gram-positive anaerobic commensals in the human gut, and thus it is likely they were also present in the faecal samples collected and used in this study. The interaction of SARS-CoV-2 with other common commensals, such as the facultative anaerobic gram-negative Escherichia coli should be investigated, too.” Comment 5: “Add discussion on which mechanisms the virus multiplies inside prokaryotic cells as we know it is an animal virus.” Response: This is a critical and insightful comment. While SARS-CoV-2 is known and generally considered an animal virus, our results suggest a potential unconventional interaction or RNA persistence within bacterial environments. We think that speculative considerations on this go beyond the scope of the paper. However, we added this final sentence at the end of the Discussion section, to explicitly state that further mechanistic work would be needed: “We are fully aware that a ‘bacteriophage-like’ behaviour of SARS-CoV-2 has not been observed nor described before, and that it is in contrast with the current knowledge of virology and molecular biology. It can’t be excluded that behind our observations and results there are new biological mechanisms not yet explored, such as those involving the interaction between anaerobic commensals of human gut and animal viruses through prokaryotic microvesicles [https://doi.org/10.1186/s12964-023-01414-8], evidently poorly studied. For this reason, we believe the findings presented in this work should be subject to controversy and verification by the scientific community. We invite other teams to verify whether they can reproduce results of this nature.” Comment 6: “Clear figure legends from Figure 1 to figure 4. The author can include here the name of the isolates.” Response: Thank you for the suggestion. We have revised all figure legends and added clarifying details to improve readability and interpretation. Comment 7: “Submit those genome and raw sequence file to NCBI or other repository.” Response: Thank you for the suggestion. We have now integrated raw sequencing data as part of the Underlying data in Zenodo: Underlying data of “Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota”, available at https://doi.org/10.5281/zenodo.5905965 . We hope these revisions address your concerns and enhance the clarity and impact of our manuscript. Thank you again for your thoughtful evaluation and the opportunity to improve our work. Dear Dr. Anwar Hossain and Dr. Md. Shaminur Rahman, We sincerely thank you for the constructive feedback on our manuscript. We appreciate the opportunity to clarify and revise our work. Below, we provide detailed responses to each of the comments raised. Comment 1: “On which basis these two bacteria were taken?” Response: As we indicated in the text, the selection of Faecalibacterium prausnitzii and Dorea formicigenerans was justified by the fact that both had previously been reported as being strongly reduced in COVID-19 patients (Ref. 17 and Ref. 18). We rephrased the Results section to better clarify this point. Comment 2: “Did they confirm that these bacteria were also present in the human gut from where they collected samples?” Response: Thank you for this comment. We did not check whether these two species were present in our collected samples. However, these bacteria are common gram-positive anaerobic commensals in the human gut, and thus it is likely they were also present in the faecal samples collected and used in this study. We have clarified this in the Discussion section by revising the text as follows: “It is important to highlight that this study is limited to SARS-CoV-2 interaction with only two bacterial strains, i.e., F. prausnitzii and D. formicigenerans, chosen because both were previously reported as strongly reduced in COVID-19 patients 17,18 . These are common gram-positive anaerobic commensals in the human gut, and thus it is likely they were also present in the faecal samples collected and used in this study.” Comment 3: “Through NGS, they sequenced the SARS-CoV-2 genome. "host specific” nucleic acid changes" Did the author sequence these genomes before inoculation to the bacterial culture? This variation might be the different variants of SARS-CoV-2 variants as these were collected from two different suspected patients. What evidence the author is going to give here as the genome changing inside the multiplication of bacterial strains?” Response: Thank you for the correct observation. We revised the text and replaced the term “host specific” with “sample-specific”. In addition, we revised the Discussion section in which this point is discussed by adding a sentence, here underlined as follows: “In our experiments, these observations might be either a consequence of different lineages already present in the supernatant aliquots of infected bacteria used in the plaque assay, or a result of the two different bacterial “cellular machinery” environments, which the virus used when infecting two different species. Both consequences cannot be excluded. However, the presence of many identified variations not specific of any lineage provides an indication that bacteria might be a potential source of novel SARS-CoV-2 mutations, and gives rise to the possibility that intra-host SARS-CoV-2 haplotypes might reflect different intestinal bacterial prior host environments of the virus.” Comment 4: “Bacteriophage potential is showing only the two isolates? What will happen if E. coli is used here?” Response: We appreciate this suggestion. Our study was a preliminary investigation focusing on human gut-resident commensals and E. coli was not included in the study. However, we acknowledge the value of using E. coli as a model organism in future studies to generalise the findings and explore potential broader bacteriophage-like interactions. This has been discussed in the revised Discussion section, by adding the following sentence: “It is important to highlight that this study is limited to SARS-CoV-2 interaction with only two bacterial strains, i.e., F. prausnitzii and D. formicigenerans, chosen because both were previously reported as strongly reduced in COVID-19 patients 17,18 . These are common gram-positive anaerobic commensals in the human gut, and thus it is likely they were also present in the faecal samples collected and used in this study. The interaction of SARS-CoV-2 with other common commensals, such as the facultative anaerobic gram-negative Escherichia coli should be investigated, too.” Comment 5: “Add discussion on which mechanisms the virus multiplies inside prokaryotic cells as we know it is an animal virus.” Response: This is a critical and insightful comment. While SARS-CoV-2 is known and generally considered an animal virus, our results suggest a potential unconventional interaction or RNA persistence within bacterial environments. We think that speculative considerations on this go beyond the scope of the paper. However, we added this final sentence at the end of the Discussion section, to explicitly state that further mechanistic work would be needed: “We are fully aware that a ‘bacteriophage-like’ behaviour of SARS-CoV-2 has not been observed nor described before, and that it is in contrast with the current knowledge of virology and molecular biology. It can’t be excluded that behind our observations and results there are new biological mechanisms not yet explored, such as those involving the interaction between anaerobic commensals of human gut and animal viruses through prokaryotic microvesicles [https://doi.org/10.1186/s12964-023-01414-8], evidently poorly studied. For this reason, we believe the findings presented in this work should be subject to controversy and verification by the scientific community. We invite other teams to verify whether they can reproduce results of this nature.” Comment 6: “Clear figure legends from Figure 1 to figure 4. The author can include here the name of the isolates.” Response: Thank you for the suggestion. We have revised all figure legends and added clarifying details to improve readability and interpretation. Comment 7: “Submit those genome and raw sequence file to NCBI or other repository.” Response: Thank you for the suggestion. We have now integrated raw sequencing data as part of the Underlying data in Zenodo: Underlying data of “Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota”, available at https://doi.org/10.5281/zenodo.5905965 . We hope these revisions address your concerns and enhance the clarity and impact of our manuscript. Thank you again for your thoughtful evaluation and the opportunity to improve our work. Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 29 Nov 2022 Mauro Petrillo , Seidor Italy srl, Milano, 21029, Italy 29 Nov 2022 Author Response Dear M. Anwar Hossain and Md. Shaminur Rahma, Thanks a lot for your valuable comments and suggestions that you have provided in the report. We will address all ... Continue reading Dear M. Anwar Hossain and Md. Shaminur Rahma, Thanks a lot for your valuable comments and suggestions that you have provided in the report. We will address all of them, and wait for those of other reviewers, in order to provide a fully revised version of the manuscript. Best regards, Mauro Petrillo, on behalf of the authors. Dear M. Anwar Hossain and Md. Shaminur Rahma, Thanks a lot for your valuable comments and suggestions that you have provided in the report. We will address all of them, and wait for those of other reviewers, in order to provide a fully revised version of the manuscript. Best regards, Mauro Petrillo, on behalf of the authors. Competing Interests: No competing interests were disclosed. Close Report a concern Author Response 14 Apr 2025 Mauro Petrillo , Seidor Italy srl, Milano, 21029, Italy 14 Apr 2025 Author Response Dear Dr. Anwar Hossain and Dr. Md. Shaminur Rahman, We sincerely thank you for the constructive feedback on our manuscript. We appreciate the opportunity to clarify and revise our work. ... Continue reading Dear Dr. Anwar Hossain and Dr. Md. Shaminur Rahman, We sincerely thank you for the constructive feedback on our manuscript. We appreciate the opportunity to clarify and revise our work. Below, we provide detailed responses to each of the comments raised. Comment 1: “On which basis these two bacteria were taken?” Response: As we indicated in the text, the selection of Faecalibacterium prausnitzii and Dorea formicigenerans was justified by the fact that both had previously been reported as being strongly reduced in COVID-19 patients (Ref. 17 and Ref. 18). We rephrased the Results section to better clarify this point. Comment 2: “Did they confirm that these bacteria were also present in the human gut from where they collected samples?” Response: Thank you for this comment. We did not check whether these two species were present in our collected samples. However, these bacteria are common gram-positive anaerobic commensals in the human gut, and thus it is likely they were also present in the faecal samples collected and used in this study. We have clarified this in the Discussion section by revising the text as follows: “It is important to highlight that this study is limited to SARS-CoV-2 interaction with only two bacterial strains, i.e., F. prausnitzii and D. formicigenerans, chosen because both were previously reported as strongly reduced in COVID-19 patients 17,18 . These are common gram-positive anaerobic commensals in the human gut, and thus it is likely they were also present in the faecal samples collected and used in this study.” Comment 3: “Through NGS, they sequenced the SARS-CoV-2 genome. "host specific” nucleic acid changes" Did the author sequence these genomes before inoculation to the bacterial culture? This variation might be the different variants of SARS-CoV-2 variants as these were collected from two different suspected patients. What evidence the author is going to give here as the genome changing inside the multiplication of bacterial strains?” Response: Thank you for the correct observation. We revised the text and replaced the term “host specific” with “sample-specific”. In addition, we revised the Discussion section in which this point is discussed by adding a sentence, here underlined as follows: “In our experiments, these observations might be either a consequence of different lineages already present in the supernatant aliquots of infected bacteria used in the plaque assay, or a result of the two different bacterial “cellular machinery” environments, which the virus used when infecting two different species. Both consequences cannot be excluded. However, the presence of many identified variations not specific of any lineage provides an indication that bacteria might be a potential source of novel SARS-CoV-2 mutations, and gives rise to the possibility that intra-host SARS-CoV-2 haplotypes might reflect different intestinal bacterial prior host environments of the virus.” Comment 4: “Bacteriophage potential is showing only the two isolates? What will happen if E. coli is used here?” Response: We appreciate this suggestion. Our study was a preliminary investigation focusing on human gut-resident commensals and E. coli was not included in the study. However, we acknowledge the value of using E. coli as a model organism in future studies to generalise the findings and explore potential broader bacteriophage-like interactions. This has been discussed in the revised Discussion section, by adding the following sentence: “It is important to highlight that this study is limited to SARS-CoV-2 interaction with only two bacterial strains, i.e., F. prausnitzii and D. formicigenerans, chosen because both were previously reported as strongly reduced in COVID-19 patients 17,18 . These are common gram-positive anaerobic commensals in the human gut, and thus it is likely they were also present in the faecal samples collected and used in this study. The interaction of SARS-CoV-2 with other common commensals, such as the facultative anaerobic gram-negative Escherichia coli should be investigated, too.” Comment 5: “Add discussion on which mechanisms the virus multiplies inside prokaryotic cells as we know it is an animal virus.” Response: This is a critical and insightful comment. While SARS-CoV-2 is known and generally considered an animal virus, our results suggest a potential unconventional interaction or RNA persistence within bacterial environments. We think that speculative considerations on this go beyond the scope of the paper. However, we added this final sentence at the end of the Discussion section, to explicitly state that further mechanistic work would be needed: “We are fully aware that a ‘bacteriophage-like’ behaviour of SARS-CoV-2 has not been observed nor described before, and that it is in contrast with the current knowledge of virology and molecular biology. It can’t be excluded that behind our observations and results there are new biological mechanisms not yet explored, such as those involving the interaction between anaerobic commensals of human gut and animal viruses through prokaryotic microvesicles [https://doi.org/10.1186/s12964-023-01414-8], evidently poorly studied. For this reason, we believe the findings presented in this work should be subject to controversy and verification by the scientific community. We invite other teams to verify whether they can reproduce results of this nature.” Comment 6: “Clear figure legends from Figure 1 to figure 4. The author can include here the name of the isolates.” Response: Thank you for the suggestion. We have revised all figure legends and added clarifying details to improve readability and interpretation. Comment 7: “Submit those genome and raw sequence file to NCBI or other repository.” Response: Thank you for the suggestion. We have now integrated raw sequencing data as part of the Underlying data in Zenodo: Underlying data of “Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota”, available at https://doi.org/10.5281/zenodo.5905965 . We hope these revisions address your concerns and enhance the clarity and impact of our manuscript. Thank you again for your thoughtful evaluation and the opportunity to improve our work. Dear Dr. Anwar Hossain and Dr. Md. Shaminur Rahman, We sincerely thank you for the constructive feedback on our manuscript. We appreciate the opportunity to clarify and revise our work. Below, we provide detailed responses to each of the comments raised. Comment 1: “On which basis these two bacteria were taken?” Response: As we indicated in the text, the selection of Faecalibacterium prausnitzii and Dorea formicigenerans was justified by the fact that both had previously been reported as being strongly reduced in COVID-19 patients (Ref. 17 and Ref. 18). We rephrased the Results section to better clarify this point. Comment 2: “Did they confirm that these bacteria were also present in the human gut from where they collected samples?” Response: Thank you for this comment. We did not check whether these two species were present in our collected samples. However, these bacteria are common gram-positive anaerobic commensals in the human gut, and thus it is likely they were also present in the faecal samples collected and used in this study. We have clarified this in the Discussion section by revising the text as follows: “It is important to highlight that this study is limited to SARS-CoV-2 interaction with only two bacterial strains, i.e., F. prausnitzii and D. formicigenerans, chosen because both were previously reported as strongly reduced in COVID-19 patients 17,18 . These are common gram-positive anaerobic commensals in the human gut, and thus it is likely they were also present in the faecal samples collected and used in this study.” Comment 3: “Through NGS, they sequenced the SARS-CoV-2 genome. "host specific” nucleic acid changes" Did the author sequence these genomes before inoculation to the bacterial culture? This variation might be the different variants of SARS-CoV-2 variants as these were collected from two different suspected patients. What evidence the author is going to give here as the genome changing inside the multiplication of bacterial strains?” Response: Thank you for the correct observation. We revised the text and replaced the term “host specific” with “sample-specific”. In addition, we revised the Discussion section in which this point is discussed by adding a sentence, here underlined as follows: “In our experiments, these observations might be either a consequence of different lineages already present in the supernatant aliquots of infected bacteria used in the plaque assay, or a result of the two different bacterial “cellular machinery” environments, which the virus used when infecting two different species. Both consequences cannot be excluded. However, the presence of many identified variations not specific of any lineage provides an indication that bacteria might be a potential source of novel SARS-CoV-2 mutations, and gives rise to the possibility that intra-host SARS-CoV-2 haplotypes might reflect different intestinal bacterial prior host environments of the virus.” Comment 4: “Bacteriophage potential is showing only the two isolates? What will happen if E. coli is used here?” Response: We appreciate this suggestion. Our study was a preliminary investigation focusing on human gut-resident commensals and E. coli was not included in the study. However, we acknowledge the value of using E. coli as a model organism in future studies to generalise the findings and explore potential broader bacteriophage-like interactions. This has been discussed in the revised Discussion section, by adding the following sentence: “It is important to highlight that this study is limited to SARS-CoV-2 interaction with only two bacterial strains, i.e., F. prausnitzii and D. formicigenerans, chosen because both were previously reported as strongly reduced in COVID-19 patients 17,18 . These are common gram-positive anaerobic commensals in the human gut, and thus it is likely they were also present in the faecal samples collected and used in this study. The interaction of SARS-CoV-2 with other common commensals, such as the facultative anaerobic gram-negative Escherichia coli should be investigated, too.” Comment 5: “Add discussion on which mechanisms the virus multiplies inside prokaryotic cells as we know it is an animal virus.” Response: This is a critical and insightful comment. While SARS-CoV-2 is known and generally considered an animal virus, our results suggest a potential unconventional interaction or RNA persistence within bacterial environments. We think that speculative considerations on this go beyond the scope of the paper. However, we added this final sentence at the end of the Discussion section, to explicitly state that further mechanistic work would be needed: “We are fully aware that a ‘bacteriophage-like’ behaviour of SARS-CoV-2 has not been observed nor described before, and that it is in contrast with the current knowledge of virology and molecular biology. It can’t be excluded that behind our observations and results there are new biological mechanisms not yet explored, such as those involving the interaction between anaerobic commensals of human gut and animal viruses through prokaryotic microvesicles [https://doi.org/10.1186/s12964-023-01414-8], evidently poorly studied. For this reason, we believe the findings presented in this work should be subject to controversy and verification by the scientific community. We invite other teams to verify whether they can reproduce results of this nature.” Comment 6: “Clear figure legends from Figure 1 to figure 4. The author can include here the name of the isolates.” Response: Thank you for the suggestion. We have revised all figure legends and added clarifying details to improve readability and interpretation. Comment 7: “Submit those genome and raw sequence file to NCBI or other repository.” Response: Thank you for the suggestion. We have now integrated raw sequencing data as part of the Underlying data in Zenodo: Underlying data of “Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota”, available at https://doi.org/10.5281/zenodo.5905965 . We hope these revisions address your concerns and enhance the clarity and impact of our manuscript. Thank you again for your thoughtful evaluation and the opportunity to improve our work. Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 09 Mar 2022 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 2 3 Version 2 (revision) 23 Apr 25 read Version 1 09 Mar 22 read read M. Anwar Hossain , University of Dhaka, Dhaka, Bangladesh Md. Shaminur Rahman , Jashore University of Science and Technology, Sadhinata Sarak, Bangladesh Didier Raoult , Aix-Marseille Université, URMITE, Marseille, France Zhonghan Sun , Fudan University, Shanghai, China Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Sun Z. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 28 May 2025 | for Version 2 Zhonghan Sun , Fudan University, Shanghai, Shanghai, China 0 Views copyright © 2025 Sun Z. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions In this article, Mauro et.al reported that SARS-CoV-2 may behave in a bacteriophage-like manner by infecting and replicating within certain human gut commensal bacteria. The authors present electron microscopy imaging, stable isotope labeling mass spectrometry, and plaque assays to support this hypothesis. While the research question is bold and potentially impactful if substantiated, several aspects of the methodology, data interpretation, and controls need to be more rigorously addressed before strong conclusions can be drawn. Major Comments: 1. The claim that SARS-CoV-2 replicates in gut bacteria is bold and unconventional. While the authors observed some viral protein signals and genome fragments in bacterial cultures, the current data cannot fully exclude alternative explanations such as uptake of viral RNA, protein adsorption, or contamination. 2. The evidence for de novo synthesis of spike protein in bacterial cultures is primarily based on ^15N-labeled peptides detected by MS. However, key supporting data such as MS/MS spectra, peptide confidence scores, and comparison with spike standard spectra are not shown. 3. The presence of virus-like particles on bacterial surfaces and within cells is interesting. Yet, without quantitative analysis or consistent morphology, the conclusions drawn from EM remain speculative. 4. The study would benefit from additional negative controls to better exclude passive adsorption or contamination. 5. The conclusion that SARS-CoV-2 replicates in gut bacteria and exhibits bacteriophage-like behavior is not fully supported by the current evidence. A more cautious interpretation is warranted. Is the work clearly and accurately presented and does it cite the current literature? Partly Is the study design appropriate and is the work technically sound? Partly Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Not applicable Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Partly Competing Interests No competing interests were disclosed. Reviewer Expertise Microbiology, cardiometabolic disease I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (0) Sun Z. Peer Review Report For: Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota [version 2; peer review: 1 approved, 2 approved with reservations] . F1000Research 2025, 11 :292 ( https://doi.org/10.5256/f1000research.180605.r380905) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/11-292/v2#referee-response-380905 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Raoult D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 28 Mar 2025 | for Version 1 Didier Raoult , Institut Hospitalo-Universitaire Méditerranée-Infection, Faculté de médecine, Aix-Marseille Université, URMITE, Marseille, France 0 Views copyright © 2025 Raoult D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions This work is very interesting, but it overturns a well-established theory about the host specificity of viruses. The idea that a mammalian eukaryotic cell virus could multiply in bacteria in a way comparable to bacteriophages is a staggering one. The techniques employed by the authors are comprehensive, ranging from electron microscopy to nucleotide sequence, proteomic evaluation and in situ hybridization. Technically, this work is indisputable. The only thing that could call into question the quality and significance of this work would be the existence of a fraud that I am unable to detect. In practical terms, I think it's very important to accept this work and subject it to controversy and verification by other scientific teams. With this in mind, our team will be moving quickly to verify whether we can reproduce results of this nature. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Not applicable Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Microbiology I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (1) Author Response 26 Apr 2025 Mauro Petrillo, Seidor Italy srl, Milano, 21029, Italy Dear Dr. Raoult, ​​​​​​We thank you for your open-mindedness and for encouraging a broader dialogue around this work. We are committed to scientific transparency, and we are pleased to read that the reviewer’s team intends to attempt replication of our results. We believe that only through open scientific discourse and independent validation can the implications of such findings be fully understood and either confirmed or refuted. For this reason, the following sentence has been added at the end of the paper: “ We are fully aware that a ‘bacteriophage-like’ behaviour of SARS-CoV-2 has not been observed nor described before, and that it is in contrast with the current knowledge of virology and molecular biology. It can’t be excluded that behind our observations and results there are new biological mechanisms not yet explored, such as those involving the interaction between anaerobic commensals of human gut and animal viruses through prokaryotic microvesicles [https://doi.org/10.1186/s12964-023-01414-8], evidently poorly studied. For this reason, we believe the findings presented in this work should be subject to controversy and verification by the scientific community. We invite other teams to verify whether they can reproduce results of this nature. ” Thank you again for your thoughtful evaluation and the opportunity to improve our work. Sincerely, Mauro Petrillo, On behalf of all authors View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Raoult D. Peer Review Report For: Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota [version 2; peer review: 1 approved, 2 approved with reservations] . F1000Research 2025, 11 :292 ( https://doi.org/10.5256/f1000research.120713.r371575) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/11-292/v1#referee-response-371575 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2022 Hossain M et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 25 Nov 2022 | for Version 1 M. Anwar Hossain , Department of Microbiology, University of Dhaka, Dhaka, Bangladesh Md. Shaminur Rahman , Department of Microbiology, Jashore University of Science and Technology, Sadhinata Sarak, Bangladesh 0 Views copyright © 2022 Hossain M et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (2) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions This work is nicely designed but only two bacterial strains ( Faecalibacterium prausnitzii and Dorea formicigenerans strain) were tested here. The Major comments are listed below: On which basis these two bacteria were taken? " Faecalibacterium prausnitzii and Dorea formicigenerans strains were purchased at the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures"; Did they confirm that these bacteria were also present in the human gut from where they collected samples? Through NGS, they sequenced the SARS-CoV-2 genome. " host specific” nucleic acid changes" Did the author sequence these genomes before inoculation to the bacterial culture? This variation might be the different variants of SARS-CoV-2 variants as these were collected from two different suspected patients. What evidence the author is going to give here as the genome changing inside the multiplication of bacterial strains? Bacteriophage potential is showing only the two isolates? What will happen if E. coli is used here? Add discussion on which mechanisms the virus multiplies inside prokaryotic cells as we know it is an animal virus. Clear figure legends from Figure 1 to figure 4. The author can include here the name of the isolates. Submit those genome and raw sequence file to NCBI or other repository. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Partly Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Not applicable Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Virology, Genomics, Metagenomics, Vaccine Development We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above. reply Respond to this report Responses (2) Author Response 29 Nov 2022 Mauro Petrillo, Seidor Italy srl, Milano, 21029, Italy Dear M. Anwar Hossain and Md. Shaminur Rahma, Thanks a lot for your valuable comments and suggestions that you have provided in the report. We will address all of them, and wait for those of other reviewers, in order to provide a fully revised version of the manuscript. Best regards, Mauro Petrillo, on behalf of the authors. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Author Response 14 Apr 2025 Mauro Petrillo, Seidor Italy srl, Milano, 21029, Italy Dear Dr. Anwar Hossain and Dr. Md. Shaminur Rahman, We sincerely thank you for the constructive feedback on our manuscript. We appreciate the opportunity to clarify and revise our work. Below, we provide detailed responses to each of the comments raised. Comment 1: “On which basis these two bacteria were taken?” Response: As we indicated in the text, the selection of Faecalibacterium prausnitzii and Dorea formicigenerans was justified by the fact that both had previously been reported as being strongly reduced in COVID-19 patients (Ref. 17 and Ref. 18). We rephrased the Results section to better clarify this point. Comment 2: “Did they confirm that these bacteria were also present in the human gut from where they collected samples?” Response: Thank you for this comment. We did not check whether these two species were present in our collected samples. However, these bacteria are common gram-positive anaerobic commensals in the human gut, and thus it is likely they were also present in the faecal samples collected and used in this study. We have clarified this in the Discussion section by revising the text as follows: “It is important to highlight that this study is limited to SARS-CoV-2 interaction with only two bacterial strains, i.e., F. prausnitzii and D. formicigenerans, chosen because both were previously reported as strongly reduced in COVID-19 patients 17,18 . These are common gram-positive anaerobic commensals in the human gut, and thus it is likely they were also present in the faecal samples collected and used in this study.” Comment 3: “Through NGS, they sequenced the SARS-CoV-2 genome. "host specific” nucleic acid changes" Did the author sequence these genomes before inoculation to the bacterial culture? This variation might be the different variants of SARS-CoV-2 variants as these were collected from two different suspected patients. What evidence the author is going to give here as the genome changing inside the multiplication of bacterial strains?” Response: Thank you for the correct observation. We revised the text and replaced the term “host specific” with “sample-specific”. In addition, we revised the Discussion section in which this point is discussed by adding a sentence, here underlined as follows: “In our experiments, these observations might be either a consequence of different lineages already present in the supernatant aliquots of infected bacteria used in the plaque assay, or a result of the two different bacterial “cellular machinery” environments, which the virus used when infecting two different species. Both consequences cannot be excluded. However, the presence of many identified variations not specific of any lineage provides an indication that bacteria might be a potential source of novel SARS-CoV-2 mutations, and gives rise to the possibility that intra-host SARS-CoV-2 haplotypes might reflect different intestinal bacterial prior host environments of the virus.” Comment 4: “Bacteriophage potential is showing only the two isolates? What will happen if E. coli is used here?” Response: We appreciate this suggestion. Our study was a preliminary investigation focusing on human gut-resident commensals and E. coli was not included in the study. However, we acknowledge the value of using E. coli as a model organism in future studies to generalise the findings and explore potential broader bacteriophage-like interactions. This has been discussed in the revised Discussion section, by adding the following sentence: “It is important to highlight that this study is limited to SARS-CoV-2 interaction with only two bacterial strains, i.e., F. prausnitzii and D. formicigenerans, chosen because both were previously reported as strongly reduced in COVID-19 patients 17,18 . These are common gram-positive anaerobic commensals in the human gut, and thus it is likely they were also present in the faecal samples collected and used in this study. The interaction of SARS-CoV-2 with other common commensals, such as the facultative anaerobic gram-negative Escherichia coli should be investigated, too.” Comment 5: “Add discussion on which mechanisms the virus multiplies inside prokaryotic cells as we know it is an animal virus.” Response: This is a critical and insightful comment. While SARS-CoV-2 is known and generally considered an animal virus, our results suggest a potential unconventional interaction or RNA persistence within bacterial environments. We think that speculative considerations on this go beyond the scope of the paper. However, we added this final sentence at the end of the Discussion section, to explicitly state that further mechanistic work would be needed: “We are fully aware that a ‘bacteriophage-like’ behaviour of SARS-CoV-2 has not been observed nor described before, and that it is in contrast with the current knowledge of virology and molecular biology. It can’t be excluded that behind our observations and results there are new biological mechanisms not yet explored, such as those involving the interaction between anaerobic commensals of human gut and animal viruses through prokaryotic microvesicles [https://doi.org/10.1186/s12964-023-01414-8], evidently poorly studied. For this reason, we believe the findings presented in this work should be subject to controversy and verification by the scientific community. We invite other teams to verify whether they can reproduce results of this nature.” Comment 6: “Clear figure legends from Figure 1 to figure 4. The author can include here the name of the isolates.” Response: Thank you for the suggestion. We have revised all figure legends and added clarifying details to improve readability and interpretation. Comment 7: “Submit those genome and raw sequence file to NCBI or other repository.” Response: Thank you for the suggestion. We have now integrated raw sequencing data as part of the Underlying data in Zenodo: Underlying data of “Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota”, available at https://doi.org/10.5281/zenodo.5905965 . We hope these revisions address your concerns and enhance the clarity and impact of our manuscript. Thank you again for your thoughtful evaluation and the opportunity to improve our work. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Hossain MA and Rahman MS. Peer Review Report For: Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota [version 2; peer review: 1 approved, 2 approved with reservations] . F1000Research 2025, 11 :292 ( https://doi.org/10.5256/f1000research.120713.r154688) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/11-292/v1#referee-response-154688 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Evidence of SARS-CoV-2 bacteriophage potential...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/11-292/v2" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/11-292/v2&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/11-292/v2" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Petrillo M et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/11-292/v2/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/11-292", templates : { twitter : "Evidence of SARS-CoV-2 bacteriophage potential in human gut microbiota. Petrillo M et al., published by " + "@F1000Research" + ", https://f1000research.com/articles/11-292/v2" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/109236/180605") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "180605"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "134670": 0, "134669": 0, "259111": 0, "127017": 0, "161322": 0, "259114": 0, "127016": 0, "161323": 0, "127019": 0, "127018": 0, "156207": 0, "127020": 0, "259117": 0, "161324": 0, "156208": 0, "154690": 0, "374853": 0, "154691": 0, "160323": 0, "154688": 101, "154689": 0, "154694": 0, "160326": 0, "154695": 0, "154692": 0, "154693": 0, "160325": 0, "377676": 0, "162635": 0, "162638": 0, "162639": 0, "162636": 0, "162637": 0, "162640": 0, "138587": 0, "138588": 0, "138589": 0, "172134": 0, "172135": 0, "172133": 0, "172138": 0, "172139": 0, "172136": 0, "371567": 0, "172137": 0, "130157": 0, "172142": 0, "130156": 0, "130159": 0, "172140": 0, "130158": 0, "172141": 0, "371573": 0, "130160": 0, "371572": 0, "371575": 321, "371574": 0, "371569": 0, "161143": 0, "371568": 0, "371571": 0, "371570": 0, "161146": 0, "249211": 0, "249210": 0, "161144": 0, "161145": 0, "151934": 0, "151935": 0, "371576": 0, "151933": 0, "249212": 0, "150656": 0, "150657": 0, "137610": 0, "148371": 0, "127120": 0, "380305": 0, "380304": 0, "148372": 0, "164250": 0, "136356": 0, "166574": 0, "166575": 0, "166573": 0, "166576": 0, "166838": 0, "166839": 0, "166837": 0, "166842": 0, "166843": 0, "166840": 0, "166841": 0, "166844": 0, "369861": 0, "369860": 0, "369863": 0, "369862": 0, "369859": 0, "369868": 0, "369865": 0, "369864": 0, "369867": 0, "369866": 0, "347351": 0, "137175": 0, "347357": 0, "347356": 0, "347359": 0, "347358": 0, "347353": 0, "347352": 0, "347355": 0, "347354": 0, "347360": 0, "157412": 0, "380909": 0, "380908": 0, "380911": 0, "380910": 0, "380905": 43, "380904": 0, "380907": 0, "380906": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "980bb0b6-af00-4bfe-acd1-b5eb44f71f4e"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });